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Summary of the MRP Portfolio 
Section A 
A systematic literature review that aimed to explore the practice and beliefs of clinicians in 
relation to symptom and performance validity testing, following its endorsement by 
international professional bodies. Fourteen survey studies indicated that validity issues were 
reported in a substantial minority of assessments across medico-legal, forensic and clinical 
settings. Validity test use appears to be increasing, although the majority of clinicians 
reported to rely upon clinical judgement in their assessments, despite established research 
indicating its limited utility in detecting response invalidity. Clinical and research 
implications are discussed, particularly in light of the literature being dominated by North 
America. 
Section B  
An empirical study exploring performance and symptom validity in an NHS outpatient 
neuropsychology population. Archival data (N = 127) revealed a base rate of performance 
validity test (PVT) failure of up to 18%. A significant relationship was found between 
performance and symptom validity, as measured by the Personality Assessment Inventory 
(PAI). Furthermore, elevations in reported psychopathology were found in the PVT fail group 
compared to those who passed. Group differences in terms of demographic variables are 
explored. Findings are discussed in the context of existing literature and recommendations 
are made for future validity testing research, as well as clinical practice. 
Section C 
Appendices of supporting material.  
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Abstract 
Background: Research has shown that assessment data can be greatly affected by non-
neurological dimensions of response, such as whether an individual is trying their best. 
Professional bodies in the USA and UK have endorsed the routine use of symptom and 
performance validity tests (SPVTs) to assess for this significant source of test variance. 
However, the impact of these recommendations on clinical practice has not yet been 
synthesised.  
Method: Five electronic databases were systematically searched to identify studies exploring 
the practices and beliefs of clinicians in settings where there is opportunity for validity 
testing. Main findings are summarised and critically appraised. 
Results: A total of 14 survey studies were included. Samples were international, although the 
majority were from North America. Validity issues were identified in a substantial minority 
of forensic and medico-legal cases, and a smaller minority of clinical assessments. The rate of 
SPVT use appears to be increasing, at least in secondary gain settings. However, clinical 
judgement continues to be relied upon by the majority, despite established research indicating 
its limited utility in detecting response invalidity. 
Conclusions: There was variability in practitioners’ adherence to professional 
recommendations regarding performance and symptom invalidity, although it appears that 
North America has progressed furthest in the field. Clinical and research implications are 
discussed.   
 Key words: Performance validity, symptom validity, clinician, practice, adherence  
  
3 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
Assessment of Response Validity: A Systematic Review of Clinician Beliefs and Practices 
Psychologists have historically used standardised instruments with the intention of 
measuring brain function and symptoms; however, test data is only valid if the examinee 
exerts adequate effort. There now exists an established evidence base indicating the presence 
of significant test data not fully explained by the brain condition itself. Green, Rohling, Lees-
Haley and Allen (2001) showed that in the presence of compensation incentives, more than 
half of the statistical variance in neuropsychological test scores was explained by examinee 
‘effort’, in contrast to just 11% explained by education, and 4% by age.  Furthermore, global 
neuropsychological functioning was found to be suppressed 4.5 times more by suboptimal 
effort than severity of the brain injury. The authors highlight the vast implications of 
overlooking this source of variance. These include inappropriate diagnoses, treatment and 
social support, whilst also potentially unjustly impacting those with genuine impairments and 
service resources. 
The ability of clinicians to detect suboptimal effort using clinical judgement has come 
under scrutiny. In a classic paper, Faust, Hart, Guilmette and Arkes (1988) found that 0% of 
their neuropsychologist sample were able to identify the profiles of simulators among those 
with genuine brain injuries. Even when informed that the base rate of malingering in the data 
was 50%, identification accuracy remained at chance level. Furthermore, the vast majority of 
the neuropsychologists indicated that they were highly or very highly confident in their 
judgement.  
Research in the field has historically focused on forensic or litigating samples with 
incentive to ‘fake bad’, simply conceptualising examinee effort as malingering for financial 
gain (McMillan et al., 2009). Performance invalidity, symptom invalidity, suboptimal effort, 
response bias, dissimulation and malingering are terms used interchangeably in the literature 
(Bigler, 2012). Definitions of these terms can be found in Appendix A. The current thesis will 
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report research findings using the terms chosen by the authors to ensure the meaning is not 
altered; otherwise, symptom or performance validity will be used as these are considered the 
most accurate and least stigmatising descriptions (Larrabee, 2012).  
Symptom and Performance Validity Tests 
Validity tests attempt to offer a more objective method of assessing the validity of 
assessment data. Performance validity tests (PVTs) refer to the assessment of validity of 
performance on cognitive tasks, and symptom validity tests (SVTs) refer to the assessment of 
the validity of self-reported symptoms. SPVT will refer to both symptom and performance 
validity tests.  
Many PVTs employ a very easy forced choice verbal recognition memory task that 
appears to the examinee to be more difficult, for example, the Test of Memory Malingering 
(TOMM, Tombaugh, 1996). Scores below chance are thought to be suggestive of 
malingering due to the likelihood of purposeful selection of incorrect items. Scores below a 
cut-off based upon normative data of known clinical groups are suggested to indicate invalid 
performance, but not intent to feign (Slick, Sherman & Iverson, 1999). PVTs should not be 
sensitive to general intellectual functioning, age, education, or brain condition (Green & 
Merten, 2013).  
SVTs are concerned with the degree to which symptomatic complaint on self-report 
measures is reflective of ‘true’ symptoms, and are usually in the form of mood or personality 
inventories (such as the Minnesota Multiphasic Personality Inventory-II; Butcher, Dahlstrom, 
Graham, Tellegen & Kreammer, 1989). 
As well as ‘stand-alone’ tests that have been developed to evaluate performance or 
symptom validity, the use of ‘embedded’ measures within existing tests can be used to 
identify invalid responding without increasing testing time. 
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SPVTs, like all neuropsychological instruments, possess imperfect psychometric 
qualities which vary across tests. It has been argued that these measures should prioritise 
specificity over sensitivity, since false positive errors may have less devastating consequences 
than false negatives (Greve & Bianchini, 2004). Vickery and colleagues (2001) found the 
average level of specificity across five PVTs to be 96%, but the average sensitivity was just 
56%. This may be a factor in clinicians’ use of SPVTs in clinical practice. The multivariate 
failure model (Larrabee, 2003) was proposed to address poor sensitivity rates, whereby 
failure on two or more PVTs can be understood as indicating invalid responding. This model 
has been found to produce good sensitivity and specificity in discriminating credible 
performance (Victor, Boone, Serpa, Buehler, & Ziegler, 2009). However, the true prevalence 
in a population, or base rate, is required for more accurate interpretation (McMillan et al., 
2009). 
Professional Recommendations 
Position papers released in North America by the National Academy of 
Neuropsychology (Bush et al., 2005) and the American Academy of Clinical 
Neuropsychology (AACN; Heilbronner et al., 2009) have suggested that response invalidity 
is present in a sizeable minority of neuropsychological examinees, with higher base rates in 
secondary gain contexts (such as forensic settings). Both guidelines consider the inclusion of 
SPVTs to be a ‘medical necessity’, and to be the most valid approach in detecting response 
invalidity. Validation studies have established that more recently developed stand-alone 
SPVTs such as the TOMM possess sound psychometric properties in comparison to 
embedded tests (Tombaugh, 1996; Rees, Tombaugh, Gansler & Moczynski, 1998). 
Consequently, professional bodies have recommended a multi-method, multi-test approach, 
utilising both stand-alone and embedded measures. The use of SPVTs should also depend 
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upon the context of the assessment and patient factors (although if not employed clinicians 
should provide rationale as to why they were not utilised). In addition, clinicians should 
encourage examinees to give their best effort, and performance on SPVTs should be 
documented within reports.  
Guidance in the UK (McMillan et al., 2009) has suggested that, in line with the USA, 
SPVTs should be routinely included in neuropsychological assessments (in both forensic and 
clinical settings). The recommendations offer some limited definitive advice to clinicians, 
such as the utility of employing both stand-alone and embedded measures, to advise 
examinees to try their best and that this will be assessed, and to report carefully on SPVT 
results (e.g. ‘effort testing failed to indicate non-credible performance’). However, emphasis 
is made on the need for further research in the UK. More recently, further guidance from the 
AACN was released concerning the use of SPVTs in disability evaluations (Chafetz et al., 
2015), which recommended their use in assessing pain complaints. To date, there have been 
no systematic reviews synthesising findings on validity testing practices, despite clear 
endorsement by international professional bodies. Without an understanding of clinical 
practice, the impact of guidance, as well as outstanding needs within the profession, remain 
unknown. 
Review Aims 
This review aimed to investigate the beliefs and practices of psychologists in relation 
to symptom and performance validity testing 12 years on from the influential US position 
paper (Bush et al., 2005), and eight years following the release of guidance in the UK 
(McMillan et al., 2009). The review will focus on a target population of clinicians who work in 
settings wherein there is opportunity for validity testing. 
Main findings in light of methodological issues will be presented and synthesised, 
producing implications for future research and clinical practice. 
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AND AND 
Method 
Literature Search 
A total of five electronic databases were searched: PsycINFO, Medline, ASSIA, ERIC 
(EBSCO) and Web of Science.  
Table 1 
Electronic Search Strategy and Key Search Terms 
*denotes truncation, looks for variants of words such as malinger, malingerer, malingering. 
Study Selection 
A flow diagram illustrating retrieved papers following application of search 
limitations (English language, peer-reviewed) is presented in Figure 1. These limits were 
applied to improve the quality of studies and to produce an appropriate amount of data for the 
current review. Titles and then abstracts were screened for eligibility. Several relevant 
journals (The Clinical Neuropsychologist, Archives of Clinical Neuropsychology, and 
Clinical Psychology Review) and reference lists of identified studies were searched for 
additional papers. Experts in the field were consulted regarding any outstanding papers and, 
finally, Google Scholar was used to hand-search for remaining literature. 
Category 1: 
Clinicians 
Category 2: 
Beliefs and practices 
Category 3: 
Validity 
 
psychologist* or 
clinical psychologist* or 
neuropsychologist* or 
expert* or 
clinician* 
 
attitude* or 
belief* or 
practice*  
 
     
effort test* or 
malinger* or 
symptom validity or 
performance validity or 
validity test* or 
response bias  
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Full text screened for inclusion 
and exclusion criteria 
 25 references 
 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow Diagram Illustrating Literature Search 
Electronic database – 
PsycINFO 
384 references 
Electronic database – 
ERIC (EBSCO) 
11 references 
Electronic database – 
WEB OF SCIENCE 
275 references 
Electronic database – 
ASSIA 
24 references 
Electronic database – 
MEDLINE 
195 references 
Screened by title (474 references removed) and abstract (117 references removed) 
Duplicates removed (30 references removed) 
 
Results limited to 
English language, 
peer-reviewed 
journals 
 
192 references 
Results limited to 
English language, 
peer-reviewed 
journals 
 
8 references 
Results limited to 
English language 
 
 
 
246 references 
Results limited to 
English language, 
peer-reviewed 
journals, search 
terms in abstract 
 
19 references 
Results limited to 
English language  
 
 
 
181 references 
Met inclusion 
criteria 
1 reference 
 
Included in final analysis 
 14 references 
12 references excluded: 
PVT not main focus 
(n=5) 
Focus on 
defining/advocating 
standards of practice 
(n=5) 
Sample not clinicians 
(n=2) 
Hand search of 
references/ reviews 
2 references 
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As demonstrated in Table 2, eligibility criteria were kept broad so as to include a 
diverse range of studies and produce more generalizable findings. 
 
Table 2 
Eligibility Criteria  
Inclusion criteria 
 
Exclusion criteria 
 
Peer-reviewed journal paper 
 
Original empirical paper  
 
Primarily focused on the assessment of 
response validity 
 
 
Not written in English language 
 
Focus on defining or advocating validity 
testing standards of practice 
 
Sample not clinicians 
 
Literature Review 
Table 3 introduces the 14 papers included in the final analysis. A more detailed 
summary table of findings is provided in Appendix B.
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Table 3 
Summary of Included Studies 
 
Study Participants 
 
Design Setting 
 
 
Hirst et al. (2017) 
 
N = 654  
Licensed clinical psychologists with ≥100 post-graduate 
neuropsychological assessment hours; 21% were board 
certified in neuropsychology 
Mean years of practice = 16 
 
Online survey emailed to National 
Academy of Neuropsychology (NAN) 
and International Neuropsychological 
Society (INS) members 
9% response rate 
 
90% USA/Canada, 10% international countries 
Approximately half sample conducted assessments 
in secondary gain contexts such as forensic work, 
disability claimants, and VA hospitals 
 
Brooks, Ploetz, & 
Kirkwood (2016) 
 
N = 282 
Neuropsychologists working with children/adolescents  
Mean years of practice = 12 
 
Online survey emailed via professional 
listservs, open for eight weeks 
 
 
USA/Canada 
Majority of sample conducted clinical assessments 
but a third also conducted forensic assessments 
Mean number of assessments performed annually = 
102 
 
Schroeder, Martin, 
& Odland (2016) 
 
N = 24 
Neuropsychologists/experts (defined as being first author on 
four recent papers regarding validity testing or participation 
in the AACN response validity conference) 
Mean years of practice = 20 
 
Online survey emailed to identified 
experts 
50% response rate 
 
USA 
92% conducted clinical assessments and 91% 
forensic assessments 
87% primarily evaluated adults and 12% worked 
across the lifespan 
 
Young, Roper, & 
Arentsen (2016) 
 
N = 172 
Psychologists working with the Veterans Affairs healthcare 
system and likely practising neuropsychology 
 
Email survey, open for one month 
44% response rate 
 
USA - Veterans Affairs healthcare system 
43% conducted forensic assessments  
16% board certified 
Mean number of assessments yearly = 155 
 
Barker-Collo & 
Fernando (2015) 
 
N = 73 
Registered psychologists  
89% of sample self-identified as clinical or educational 
 
Advertised through the New Zealand 
Psychological Society and the New 
Zealand College of Clinical 
 
New Zealand 
Most respondents were clinicians working for the 
Accident Compensation Corporation (ACC) or 
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psychologists and others were ‘generalists’  
Mean years of practice = 14 years 
Psychology and provided weblink for 
online survey; open for four months 
 
privately; minority also conducted medico-legal 
assessments  
 
 
Martin, Schroeder, 
& Odland (2015) 
 
N = 316 
Licensed neuropsychologists who primarily assess adults 
Mean years of practice = 12 
 
Online survey based on previous 
surveys, sent via professional 
neuropsychology email listservs and 
open for approximately three weeks 
 
 
USA 
Majority (33%) worked in private practice, and 
73% of sample did at least some forensic 
assessments 
 
 
Allcott et al. (2014) 
 
N = 73 
Multi-disciplinary experts at consultant level (psychologists, 
psychiatrists, orthopaedic specialists, neurologists, & 
occupational therapists) 
 
Emailed to members of the Directory 
of Expert Witnesses as well as other 
known experts; open for six months 
25% response rate 
 
UK 
Medico-legal settings  
 
Dandachi-
Fitzgerald, Ponds, 
& Merten (2013) 
 
N = 515 
96% psychologists, 3% physicians 
Mean years of practice = 10 
 
 
Email survey sent to chairs of each of 
the European Societies of 
Neuropsychology to forward to 
respective members; six of 12 societies 
agreed to participate 
Survey open for 18 months 
Range of 6-25% response rates  
 
Surveyed 6 European countries (Germany, Italy, 
Denmark, Finland, Norway, Netherlands) 
95% conducted clinical assessments, 55% 
undertook forensic work 
Median assessments conducted in previous year = 
70 
 
McCarter, Walton, 
Brooks, & Powell 
(2009) 
 
N = 130 
Psychologists and neuropsychologists 
 
Survey emailed to members of the BPS 
Division of Neuropsychology 
22% response rate  
 
UK 
70% of sample conducted both clinical and forensic 
assessments, 29% solely clinical and 1% solely 
forensic 
 
Sharland & Gfeller 
(2007) 
 
N = 188 
Clinical neuropsychologists (30% board certified in 
neuropsychology) 
Mean years of practice = 17 
 
Paper surveys mailed to a random 
sample of approximately one third of 
NAN professional members  
26% response rate 
 
USA 
Unknown practice settings or proportion of 
clinical/forensic assessments conducted 
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Boccaccini, 
Boothby, & 
Overduin (2006) 
 
 
N = 116 
Pain specialists and clinical-forensic psychologists  
34% had specialised training in forensic and pain assessment 
 
Mailed questionnaire (including a 
vignette describing an attorney-referred 
case) to members of the American Pain 
Society, and relevant divisions of the 
American Psychological Association 
Asked respondents whether they would 
attempt to assess response validity, and 
methods they would use 
18% response rate 
 
USA 
Personal injury and medico-legal settings 
 
Sullivan, Lange, 
& Dawes (2006) 
 
N = 17 
Members of the Australian Psychological Society, College of 
Clinical Neuropsychology and delegates from two 
Australian neuropsychology conferences  
Mean years of practice = 13 years 
 
Emailed an online survey 
 
 
Australia 
64% worked in private practice settings 
60% of respondents’ work was clinical assessment 
and the remainder forensic work 
 
Slick, Tan, Strauss, 
& Hultsch (2004)  
 
N = 24 
Neuropsychologists who were identified as experts in the 
area of civil litigation through their publication history  
55% board certified in neuropsychology 
Mean years of practice = 15 
 
Survey completed via email or over the 
telephone across a three month period 
61% response rate 
 
 
USA 
Clinical and medico-legal settings 
Majority (71%) had undertaken >20 assessments in 
the previous year 
 
 
Mittenberg, Patton, 
Canyock, & Condit 
(2002) 
 
N = 144 
Members of the American board of neuropsychologists who 
were listed as actively practising as neuropsychologists  
Mean years of practice = 18 
 
Paper surveys were mailed 
37% response rate 
 
 
USA/Canada 
Respondents engaged in both clinical and medico-
legal/forensic work 
Mean number of assessments undertaken yearly = 
252 
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Design of Studies  
All studies employed a survey design to investigate beliefs and practices regarding 
SPVTs. Most developed an idiosyncratic questionnaire using software such as 
SurveyMonkey™ (SurveyMonkey Inc., 2015) based upon previous survey research in 
validity test use, which was adapted to suit the target audience. Conversely, Allcott et al. 
(2014) and McCarter, Walton, Brooks, and Powell (2009) designed a novel questionnaire 
based on the authors’ clinical experience. Questionnaires were reported to examine 
participants’ demographics, training and clinical practice, use of SPVTs and rationale, and 
practices regarding suspected invalid performance. Hirst et al. (2017) focussed specifically on 
adherence to validity testing recommendations, and Boccaccini, Boothby, and Overduin 
(2006) used a clinical vignette to investigate participants’ hypothetical SPVT approaches. 
Five out of the 14 studies provided access to the questionnaire used. 
Participants 
The majority of samples included clinical psychologists, neuropsychologists, and 
experts with a doctoral degree, practicing within the field of neuropsychology in at least a 
part-time capacity.  
Schroeder, Martin, and Odland (2016), as well as Slick, Tan, Strauss, and Hultsch 
(2004), investigated experts in the field of neuropsychological validity testing, which was 
defined as identification as first author on two recent papers regarding validity testing. Young, 
Roper, and Arentsen (2016) sampled psychologists employed within the Veterans Affairs 
(VA) healthcare system; a large, integrated system in the USA involving both healthcare 
provision and disability assessment.  
Allcott et al. (2014) presented the only investigation of multi-disciplinary 
professionals at consultant level within personal injury settings, including psychologists, 
14 
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psychiatrists, neurologists, and occupational therapists. Brooks, Ploetz, & Kirkwood (2016) 
sampled professionals who conducted assessments of children and adolescents, and 
Boccaccini et al. (2006) involved pain specialists and forensic psychologists. 
Studies were predominantly based in North America and Canada. However, two were 
based in the UK (Allcott et al., 2014; McCarter et al., 2009), one was in Australia (Sullivan, 
Lange, & Dawes, 2006), and one was in New Zealand (Barker-Collo & Fernando, 2015). 
Additionally, Hirst et al. (2017) surveyed international neuropsychologists (although largely 
in the USA), and another study surveyed neuropsychologists across six European countries; 
Germany, Italy, Denmark, Finland, Norway and the Netherlands (Dandachi-Fitzgerald, 
Ponds, & Merten 2013).  
The work settings of the participants varied; half of the surveys noted that respondents 
completed more clinical assessments than forensic, although the majority also completed 
some medico-legal work. The samples used by Allcott et al. (2014), Boccaccini et al. (2006), 
and Sullivan et al. (2006) completed only forensic, legal or disability claim cases. Barker-
Collo and Fernando (2015) reported that most of their sample were employed in treatment 
settings in Accident Compensation Corporation (ACC)-funded and private practice in New 
Zealand. Similarly, the majority of the American neuropsychologists sampled by Hirst et al. 
(2017) practiced in settings where secondary gain was likely. In a UK study (McCarter et al., 
2009), the majority (70%) of neuropsychologists reported conducting both clinical and 
forensic assessments, with a third completing solely clinical work and 1% solely forensic 
work. 
All but one study investigated professionals working with adults, Brooks et al. (2016) 
being the only researchers exploring the use of SPVTs with children and adolescents. The 
vast majority of studies investigated professionals in the field of neuropsychology; however, 
Boccaccini et al. (2006) focussed on pain complaints in personal injury claims. Two studies 
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investigated the experiences of neuropsychologists working with clients presenting with a 
range of diagnoses such as head injury, PTSD, fibromyalgia, and mood disorders (Young et 
al., 2016; Mittenberg, Patton, Canyock, & Condit, 2002). 
The clinical experience of the sample varied across studies, ranging from a mean of 
10 years (Dandachi-Fitzgerald et al. 2013) to 20 years in the study by Slick et al. (2004), 
which sampled experts. Four studies did not provide data on years of experience. 
Where reported, the mean number of assessments performed annually ranged from 30 
(Dandachi-Fitzgerald et al., 2013) to 155 per respondent (Young et al., 2016).  
Procedures 
The majority of studies emailed participants a link to an online survey via broad list 
servers in the field, such as AACN, NPSYCH, and the British Psychological Society 
(Division of Neuropsychology). Dandachi-Fitzgerald et al. (2013) contacted the chairs of the 
European Societies of Neuropsychology and requested that they forward an email link to 
members of their respective societies, translated into their native languages if requested. 
Allcott et al. (2014) distributed their survey via email to experts identified from the Directory 
of Expert Witnesses, and, likewise, Slick et al. (2004) identified experts using PsycINFO 
searches. Sullivan et al. (2006) additionally invited conference attendees to take part and 
Barker-Collo and Fernando (2015) recruited their participants in professional society 
newsletters.  
Main Findings 
Base rates. Professionals’ estimates of base rates of invalid performance were 
explored in the majority of studies. Dandachi-Fitzgerald et al. (2013) found that the base rate 
of ‘insufficient effort’ was estimated to be 10% in clinical assessments and 15% in forensic 
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assessments in their sample of neuropsychologists from six European countries. 
‘Malingering’ was thought to occur in 4% of their clinical cases and 10% of forensic cases. 
Interestingly, a discrepancy was found between general estimated base rates of malingering 
and respondents’ estimates of base rates in their own practice (general estimates were rated as 
10% in clinical and 20% in forensic assessments). This suggests that neuropsychologists in 
the study believed that they personally encountered less malingering clients than their 
colleagues. 
A quarter of Barker-Collo and Fernando’s (2015) sample of psychologists 
predominantly working in treatment settings in ACC-funded and private practice indicated 
that performance invalidity issues occurred in 20-50% of cases. Hirst et al. (2017) also 
surveyed clinicians mostly practicing in secondary gain contexts, and found that respondents 
who followed validity testing recommendations reported significantly higher base rates of 
‘poor effort’ and ‘malingering’ than those who did not follow all practice recommendations. 
Approximately half of the experts surveyed by Slick et al. (2004) considered base 
rates of ‘possible malingering’ to be at least 10%, and a third considered rates to be at least 
20%. Furthermore, two-thirds considered there to be the presence of ‘definite malingering’ in 
at least 10% of cases. This is in line with Mittenberg et al. (2002), who found base rates of 
‘probable malingering’ and ‘symptom exaggeration’ were estimated to be approximately a 
third of disability evaluations and personal injury cases, and 8% of medical cases in their 
sample of North American neuropsychologists. Estimated base rates did not vary greatly 
across practice settings or geographic regions, or the number of assessments conducted 
annually.  
Young et al. (2016) found that the base rate of SPVT failure as reported by 
neuropsychologists conducting routine outpatient clinical evaluations within the VA 
healthcare system was approximately 23% (three times that found by Mittenberg, et al. 2002). 
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The highest rate of SPVT failure was found in mild traumatic brain injury (mTBI) and PTSD 
disability evaluations, consistent with Mittenberg et al. (2002). Higher rates of SPVT failure 
were associated with clinician factors, such as practice being more focused on 
neuropsychological assessment, and greater frequency of SPVT usage; the less clinicians 
used SPVTs, the fewer failures they found (Young et al., 2016). There was no relationship 
between base rate of failure estimates and board certification in neuropsychology status, but 
there was a positive correlation between number of SPVTs used and professional organisation 
memberships (p<.02). 
Allcott et al. (2014) found that 70% of their sample of UK multi-disciplinary 
consultants within personal injury settings indicated that three quarters of cases were 
‘genuine’; however, 25% considered half of their cases to be ‘disingenuous’. Base rates of 
‘symptom exaggeration’ in personal injury cases in Australia was 13%. Criminal cases 
received the highest estimate (17%) and medical or psychiatric the lowest (3%; Sullivan et 
al., 2006). 
Using a relatively large and broad sample of US neuropsychologists, estimations of 
base rates of ‘deliberate exaggeration’ in medico-legal assessments was on average 20%, and 
5% in cases with no obvious secondary gain (Sharland & Gfeller, 2007), similar to the 
findings of Mittenberg, et al. (2002) and Slick et al. (2004). 
Overall, findings consistently suggested that a substantial minority of forensic and 
medico-legal cases and a smaller minority of clinical assessments were considered by 
professionals to produce invalid performances across a range of geographical locations. 
Estimated base rates in clinical evaluations were between 3 and 10%, in forensic cases 
estimates were 17-25%, and were variable in litigation settings (between 8-30%, the lowest 
estimates being found in New Zealand and the highest in North America). 
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The literature suggests that professionals’ views of base rates have remained relatively 
stable over time, with medico-legal case estimates around 20-30% in 2002, to approximately 
20% in 2007, 25% in 2004, and between 18-25% in 2017. Base rates of clinical assessments 
were estimated around 8% in 2002, 3% in 2005, 5% in 2007, and 10% in 2013. 
Methods. Although base rates were relatively comparable, methods employed to 
assess response validity varied throughout the papers. The respondents investigated by 
Brooks et al. (2016) considered the assessment of validity to be ‘multi-factorial’, but mostly 
relied upon behavioural observations and discrepancies between self-report and records in 
their evaluations of children and adolescents. Furthermore, despite scores below cut-offs on 
stand-alone SPVTs receiving the most empirical support, these were only the seventh most 
popular method. This may indicate that the respondents based their decisions on factors other 
than independent research. 
Similarly, Barker-Collo and Fernando (2015) found that their sample of registered 
psychologists in New Zealand was most likely to use clinical judgement to assess for 
performance validity (47%), with only 38% reporting use of embedded SPVTs. 
Martin et al. (2015) found that when there was a discrepancy between SPVTs and 
qualitative measures of validity, the majority would have more confidence in SPVT results 
but a significant minority (13%) would give more weight to clinical judgement. The greatest 
proportion of respondents (35%) in this study indicated that they considered two or more 
‘failures’ on PVTs to indicate questionable validity. 
Both Sullivan et al. (2006) and Mittenberg et al. (2002) found that approximately two-
thirds of their samples endorsed qualitative methods of assessing validity, such as 
inconsistencies in pattern of performance, severity of cognitive impairment, self-report and 
documented condition, whilst around half relied upon scores below cut-offs on SPVTs. 
Schroeder et al. (2016) similarly found that their sample used a broad range of methods to 
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assess validity, integrating both quantitative and qualitative methods. The majority of experts 
have also been found to rely upon discrepancies between self-reports and medical history, and 
complaints inconsistent with the severity of the condition (Allcott et al., 2014).  
In a sample of specialists conducting pain assessments, the most popular method for 
assessing the validity of pain symptoms was to review collateral information in relation to 
pain symptoms, such as medical records, observations of pain-related behaviours and 
discrepancies between pain complaints and test data (Boccaccini et al., 2006). 
Overall, the majority of studies suggested that the most commonly relied upon 
methods of detecting invalid responding were qualitative, and included clinical judgement in 
relation to inconsistencies between pattern of performance and condition, implausible self-
reported symptoms, and inconsistencies between severity of symptoms and condition. 
Frequency and manner of SPVT use. The vast majority of the studies reviewed 
reported on the frequency with which SPVTs were used by their respective samples of 
practitioners. 
Around half of a sample of North American neuropsychologists reported they often or 
always included an SPVT in their assessments (Sharland & Gfeller, 2007); however, this had 
increased to 92% in a similar sample eight years later (Martin et al., 2015). The latter study 
also found that the use of embedded measures was more than 14 times greater than in 
Sharland and Gfeller’s (2007) sample previously. Furthermore, the likelihood of using stand-
alone measures was more than six times greater. However, the authors found no change in the 
popularity of using qualitative methods to assess invalidity which remained high. Similarly, 
approximately two-thirds of US respondents in 2016 indicated that they used SPVTs always 
or frequently across clinical and forensic contexts (Young et al., 2016), including both stand-
alone and embedded measures.  
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According to the most recent survey in 2017, those who reportedly adhered to validity 
testing recommendations included a greater number of SPVTs in assessments on a routine 
basis in comparison to those who did not meet recommendations (an average of 10 measures 
compared to 5.8, p<.001; Hirst et al., 2017). Young et al. (2016) found that when respondents 
used SPVTs, the majority employed at least two stand-alone or embedded measures, but there 
was no consensus regarding the use of one or two SPVT failures to indicate invalid 
performance.  
Consistent with Sharland and Gfeller (2007), Dandachi-Fitzgerald et al. (2013) found 
that European respondents indicated a greater occurrence of invalid responding than their use 
of SPVTs. Despite acknowledging the prevalence of invalid performance, 69% of 
respondents reported they often or always based their judgements on qualitative methods 
such as discrepancies between self-reports, records, and condition severity. Only 11% 
indicated systematically using SPVTs in clinical assessments, and just 44% in forensic 
assessments across the whole sample. Respondents in Norway were most likely to use SPVTs 
(86% in the majority of the forensic assessments and 54% in the majority of clinical 
assessments). Respondents in Italy reported the lowest rate of SPVT use (13% and 10% in the 
majority of forensic and clinical assessments respectively). 
In a UK sample of neuropsychologists, more than 95% of those working within 
medico-legal settings indicated that they always commented on the examinee’s approach to 
testing and level of co-operation, as well as 76% of those working in clinical settings 
(McCarter et al., 2009). However, validity testing was reported by only 59% to be 
incorporated into their medico-legal examinations. In addition, only 11% reported using 
SPVTs most of the time, and the majority indicated that they employed SPVTs rarely.  
The rate of experts’ SPVT use was found to be higher than non-experts; Schroeder et 
al. (2016) found that more than 90% of experts used both stand-alone and embedded SPVTs 
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in their assessments, and the majority reported that they gave more weight to SPVT results 
that their initial clinical judgement. The majority (79%) of experts in the study by Slick et al. 
(2004) used at least one SPVT per assessment, and all respondents who employed a fixed 
battery approach reported they included an SPVT routinely. In pain settings, 71% indicated 
that they assessed the validity of pain complaints, and this was comparable across pain and 
forensic specialists (Boccaccini et al., 2006). However, Allcott et al. (2014) found that 40% 
of their multi-disciplinary expert sample in UK personal injury settings indicated they did not 
express opinion on the validity of performance as a matter of course, and 11% had never 
considered performance validity. Unsurprisingly, 44% of respondents reported they did not 
routinely administer SPVTs.  
In addition, Brooks et al. (2016) found that participants reported frequently using 
SPVTs in their assessments with children and adolescents; 92% reported they used at least 
one stand-alone or embedded validity test per assessment and an average assessment would 
include one stand-alone PVT, one-to-two embedded PVTs, and one-to-two embedded SVTs. 
Interestingly, this far exceeds that reported in several other studies using adult samples. The 
number of validity tests used per assessment with children and adolescents was not affected 
by the clinicians’ level of training. 
Lastly, clinicians conducting forensic evaluations were more likely than those solely 
working clinically to employ stand-alone SPVTs, both with adults (Slick et al., 2004) and 
children (Brooks et al., 2016).  
In summary, the frequency of SPVT use was variable across evaluation setting, 
geographical location, and client characteristics. It appears that over time, the rate of SPVT 
use has increased, however, and validity testing recommendations are being more closely 
adhered to (Hirst et al., 2017).  
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In terms of the tests used to validate performance, a broad range of stand-alone and 
embedded measures were listed by study respondents; more detail can be found in Appendix 
B. By far the most commonly utilised stand-alone SPVT across the studies was the Test of 
Memory Malingering (TOMM; Tombaugh, 1996), in all but one study. Sharland and Gfeller 
(2007) found that as well as being the most frequently utilised test, professionals also had the 
greatest confidence in the TOMM; classification accuracy was rated at 7.5/10. In addition, the 
five highest ratings for classification accuracy were given to stand-alone tests; however, only 
the TOMM was among the 10 most frequently utilised PVTs. 
The most popular SVT across studies was the MMPI-II, which was more widely used 
in the USA and New Zealand (Sharland & Gfeller, 2007; Barker-Collo & Fernando, 2015) 
than in the UK (McCarter et al., 2009). 
In terms of validity measures embedded within existing tests, several of the studies 
found Reliable Digit Span (a calculation derived from the Digit Span subtest of the Wechsler 
Adult Intelligence Scale - Revised, Wechsler, 1981; Greiffenstein, Baker, & Gola, 1994) to 
be the most utilised (Brooks et al., 2016; Young et al., 2016; Martin et al., 2015; Sharland & 
Gfeller, 2007), along with the California Verbal Learning Test-II and Children’s Version 
(CVLT-II and CVLT-C; Delis, Kaplan, Kramer, & Ober, 1994, 2000), a test of semantic 
verbal list learning.  
 Interestingly, none of the pain specialists surveyed by Boccaccini et al. (2006) 
endorsed any measure specifically intended to assess symptom validity. Qualitative 
comments suggested that respondents relied upon general pain and coping measures, despite 
none of the measures cited incorporating validity scales (for example, the McGill Pain 
Questionnaire; Melzack,1975). 
Beliefs regarding validity testing. Martin et al. (2015) found that a vast majority 
(98%) of US neuropsychologists surveyed considered validity testing to be mandatory within 
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forensic assessments. Just 55% of the sample believed SPVTs to be mandatory in clinical 
settings, however, with 38% believing tests to be desirable. This is in contrast to McCarter et 
al. (2009) who found fewer still considered validity testing to be mandatory in UK clinical 
contexts (5-7%); 16% felt that validity testing was unnecessary in clinical assessments. 
Approximately 70% of neuropsychologists surveyed by Hirst et al. (2017) believed 
that an SPVT should be included in every assessment. Of those who indicated they followed 
recommendations, a significantly greater number practised in adult settings compared to 
paediatric or geriatric settings (89% and 10% respectively), than those not following validity 
testing guidelines (64% and 35% respectively, p<.001). 
Slick et al. (2004) explored the confidence of North American experts in their own 
abilities to detect ‘exaggerated or faked deficits’. The average rating provided was 7.75/10, 
and ratings were weakly correlated with reported base rates of ‘definite malingering’, but 
were strongly correlated with estimates of ‘possible malingering’ (r=-.13, p=.44 and r=-.79, 
p<.01 respectively). This suggests that lower confidence in ability to detect malingering was 
reported by those who estimated a higher prevalence of malingering. 
In terms of the presentations most likely be subject to validity concerns, Allcott et al. 
(2014) found that respondents provided the highest ratings for pain (headache; 50%) and 
cognitive complaints (35%). However, pain specialists who had not undertaken forensic 
training made several qualitative comments appearing to dispute the necessity of validating 
pain symptoms in the study by Boccaccini et al. (2006), including: “Pain is a subjective 
experience. Experts in pain are taught to believe the patient’s reports. Diagnostic tests are not 
as useful for pain conditions as other medical problems” (p. 59). 
The experts sampled by Schroeder et al. (2016) largely agreed with a general 
neuropsychologist sample regarding validity testing and were similarly knowledgeable about 
current recommendations (Martin et al., 2015). The latter study found a significant 
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relationship between validity testing beliefs and the number of articles read. The authors 
compared high and low readership groups and found that 62% respondents in the high 
readership group considered validity testing to be mandatory versus 40% in the low 
readership group (p<.001). The high readership group was also significantly more likely to 
strongly agree with the statement that “validity testing is more accurate than clinical 
impressions in determining patient credibility” than the low readership group (58% versus 
33%, p<.001).  
Likewise, Allcott et al. (2014) found that 55% of their UK sample were not able to list 
any peer-reviewed literature on the subject of performance validity, and half of respondents 
who indicated they routinely used SPVTs could not name any peer-reviewed research. 
Justifications for use. The psychologists surveyed by Barker-Collo and Fernando 
(2015) reported they would decide whether to utilise SPVTs based upon various client 
characteristics, such as the presence of secondary gain, or unusual symptoms or history. 
Respondents reported using SPVTs due to endorsement by professional boards, awareness of 
support in the literature, to safeguard the validity of conclusions drawn, and to improve client 
care. Reasons provided for not using SPVTs included practical challenges such as time 
constraints, limited access to tests, and lack of training or experience. Comments also 
indicated that clinicians’ reservations were concerned with the notion that validity testing 
does not reveal underlying motivations, and disapproval of using deception with clients. 
Dandachi-Fitzgerald et al. (2013) found that SPVTs were not utilised in the presence 
of severe cognitive impairment. Furthermore, 23% of respondents indicated that they 
believed clinical cases to ‘rarely malinger or exaggerate’, and 23% felt that symptom 
invalidity was obvious from the examinees’ presentation or from performance in other tests. 
Reasons provided for using SPVTs were related to awareness of the literature, SPVTs being 
necessary to validate other findings, and in line with recommendations from professional 
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bodies. A significantly greater number of respondents reported they utilised SPVTs “to cover 
my back” (p. 780) in comparison to the UK psychologists sampled by McCarter et al. (2009; 
31% and 18% respectively, p<.01). 
The most frequently reported justification for SPVT use in the UK study by McCarter 
et al. (2009) was the endorsement by the scientific and professional literature, as well as the 
need to validate the assessment findings overall. The most commonly endorsed reason for not 
including SPVTs was related to the belief that invalid responding was obvious from 
observations or other test results (29%). Respondents also reported that time constraints and a 
perception of low base rates of ‘malingering’ in clinical cases were justifications for the 
exclusion of SPVTs in assessments (27% and 26% respectively). 
Allcott et al. (2014) also discovered scepticism in relation to validity testing in 
experts, who commented that “history and examination are best indicators”, “validity of such 
instruments remains questionable”, and “I am unaware of any reliable tests or procedures that 
are of help” (p. 72).  
Providing warning. Where reported, all studies indicated that respondents 
encouraged the majority of examinees to do their best when beginning an assessment. 
Findings were more mixed on providing explicit warning that examinees would be 
completing tests sensitive to invalid performance, particularly in forensic assessments 
(Dandachi-Fitzgerald et al., 2013). Furthermore, Hirst el al. (2017) found that US 
neuropsychologists were significantly less likely than non-US respondents to provide explicit 
warning (22% and 32% respectively, p=.003). Clinicians working with children and 
adolescents were even less likely to disclose use of SPVTs (8% explicitly stated use; Brooks 
et al., 2016). 
Interpretation. Professionals also had differing views on how to interpret SPVT 
failure. Schroeder et al. (2016) found that experts considered malingering to be the most 
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likely cause of SPVT failure in forensic settings, but a very infrequent cause of failure in 
clinical settings. Experts considered other factors, such as somatoform or conversion 
disorder, psychiatric issues or attitude towards testing (oppositional, non-compliant or 
indifferent behaviour), to be underlying SPVT failure in clinical contexts, although there was 
no consensus as to common underlying mechanisms. 
The respondents surveyed by Martin et al. (2015) reported that the most likely cause 
of test invalidity in clinical cases was psychiatric issues (not including somatoform or 
conversion disorder). However, the most likely cause of SPVT failure in forensic settings was 
reported to be malingering. Malingering was listed to be the sixth most common reason for 
invalid responding in clinical settings. The least common underlying causes in both clinical 
and forensic settings were genuine cognitive impairment, and diagnosis threat.  
A vast majority of the studies found that respondents preferred to report that test 
results were ‘inconsistent with severity of injury’, and that ‘no firm conclusions can be 
drawn’ (Dandachi-Fitzgerald et al., 2013; Sharland & Gfeller, 2007; Mittenberg, et al., 2002; 
Martin et al., 2015). Experts were more likely than general neuropsychologists to report that 
test data was invalid when SPVTs had been failed, as well as those practising in the USA 
compared to non-US clinicians (Slick et al., 2004; Sharland & Gfeller, 2007). More 
pejorative terms such as ‘malingering’ were not favoured by respondents across the studies. 
Martin et al. (2015) found that only 11% would use the term malingering, which is half that 
found eight years earlier (Sharland & Gfeller, 2007). However, experts were more likely than 
general clinicians to use this term (Schroeder et al., 2016). Findings also showed that most 
respondents preferred the professional term ‘PVT’ (74%), and just 14% preferred using 
‘effort measure’. Interestingly, 23% of those surveyed by Young et al. (2016) reported using 
the terms somatoform (excessive somatic complaints) and cogniform (excessive cognitive 
complaints) labels when reporting on invalid test results, despite there currently being no 
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empirical support for SPVT failure being explained by these psychiatric conditions to the 
author’s knowledge. 
Of a multi-disciplinary sample of experts, 46% indicated they felt it to be desirable to 
know the amount of compensation being claimed when forming an opinion on response 
validity (Allcott et al., 2014).  
Feedback and management. In terms of managing suspected invalid performance, a 
diverse range of responses was reported. The majority of an expert sample indicated they 
rarely or never confronted the examinee (Schroeder et al., 2016). This is significantly less 
likely than was found in a prior expert survey (0% versus 25%, p<.01; Slick et al., 2004) as 
well as in general neuropsychologists (4% versus 23%, p<.01; Martin et al., 2015).  
Participants across the studies were split on ways of responding when suspecting 
invalid performance; the majority indicated they would administer additional SPVTs, some 
would continue as normal, and a smaller minority would discontinue (Martin et al., 2015; 
Dandachi-Fitzgerald et al., 2013; Slick et al., 2004; Hirst et al., 2017; Brooks et al., 2016). 
Interestingly, in forensic cases, neuropsychologists were more likely to continue as planned 
(75%) than to terminate the assessment (20%; Martin et al., 2015).  
Concerningly, Hirst et al. (2017) reported that approximately one third of respondents 
indicated they mostly or always continued to interpret the assessment as usual even when 
SPVTs had been failed.  
Critical Review 
Papers were critiqued using the Center for Evidence Based Management Quality 
Appraisal Tool for surveys (CEBMa; 2014); Appendix C. This tool was chosen as it 
specifically critiqued surveys and therefore allowed for a more thorough comparison of 
studies that were highly homogenous in design. For example, the CEBMa Tool includes items 
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relating to survey selection bias and response rate, factors that may have been overlooked 
using a more general appraisal tool.  
Table 4 illustrates the ratings for each study. The main methodological issues will be 
discussed in turn, followed by synthesised findings in light of the limitations discussed, with 
implications for further research and clinical practice. 
All studies scored relatively comparably on the CEBMa appraisal tool, achieving 
between 36-55% of checklist items. Studies differed on their scores for response rate, 
statistical analysis and potential for confounding variables. 
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Table 4.  
Results of Quality Appraisal (Center for Evidence Based Management, 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Y = yes, N = no, U = unclear; Shaded areas identify failed items; Criteria 12 excluded as not relevant to current review; a Reverse scoring
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Sample Representativeness 
The majority of studies included samples that well represented their target population 
based on their focused question or issue. Half of the studies reviewed aimed to find out the 
general practices and beliefs of neuropsychologists and therefore sampled broadly without a 
priori hypotheses. Sharland and Gfeller (2007) surveyed a random sample of approximately 
one-third of members of a professional body, which may have decreased non-response bias 
and potentially increased the representativeness of the sample. 
Four studies intended to explore the practices of experts and specialists within 
litigation settings and sampled using a variety of methods (Schroeder et al., 2016; Allcott et 
al., 2014; Boccaccini et al., 2006; Slick et al., 2004). Schroeder et al. (2016) and Slick et al. 
(2004) sampled more broadly and applied inclusion and exclusion criteria to define expert 
status. However, the former applied more stringent criteria making the sample more likely to 
represent experts in the field. Allcott et al. (2014) contacted all experts registered on the 
Directory of Expert Witnesses which is likely to have produced a sample representative of the 
target population. Although it was not possible to verify credentials of the VA healthcare 
clinicians surveyed by Young et al. (2016), it appears that due to the clinical activities 
reported by the sample, the population was relatively well represented.  
Unfortunately, the generalisability of some studies was limited by poor response rates. 
Despite initially aiming to investigate international adherence to guidelines, only a small 
minority of international responses were received by Hirst et al. (2017), and the survey was 
only disseminated in English. Similarly, Brooks et al. (2016) received insufficient responses 
from practitioners working with the youngest children (below five years), limiting the 
generalisability of their findings to paediatric neuropsychologists. Furthermore, only six 
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countries agreed to participate in the study by Dandachi-Fitzgerald et al. (2013) which was 
intended to represent European practitioners. 
Although all samples were scored as acceptable in terms of representativeness on the 
CEBMa checklist, some studies increased accessibility and generalisability of findings 
through appropriate and thorough dissemination to their target populations. 
Selection Bias 
All studies scored poorly on the CEBMa checklist due to using self-selecting or 
convenience sampling methods to greater or lesser extents, which inevitably introduces some 
level of bias. Nevertheless, performance validity is a trending topic in neuropsychology 
currently so can be considered relevant to most in the profession (Bigler, 2014). 
A high level of selection bias is likely in the study by Barker-Collo and Fernando 
(2015) due to the sampling method of advertising the study in professional society newsletter; 
it is likely that those who responded were highly motivated to take part and may have had 
particular views on the topic.  
The broad sampling method used by Dandachi-Fitzgerald et al. (2013) increased the 
risk of non-response bias, as not all of the participants approached would have conducted 
neuropsychological assessments. There was no way of discerning to what extent non-
response bias affected the findings; however, the authors attempted to counter this by 
comparing findings to similar surveys in the USA and UK.  
Sampling bias may also have been problematic in the survey by Brooks et al. (2016) 
due to the method of using an open online survey. However, in order to counter this the 
authors invited views of both practitioners regularly using SPVTs and those who did not. 
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Sample Size 
Sample sizes varied throughout the studies reviewed. The mean sample size across all 
samples was 194 participants, with a range of 17 - 654. Power analysis was not conducted by 
any of the papers, meaning all studies scored poorly on this item on the CEBMa checklist. 
Even without power calculations, it was clear that some studies suffered from small 
samples that ultimately impacted the robustness of the conclusions drawn. For example, the 
samples of five of the studies were under 100 (including N=17 in Sullivan et al., 2006, and 
N=24 in Schroeder et al., 2016). The majority of studies included sample sizes between 100 
and 300, although it is noted that the sample of McCarter et al. (2009) was comparable to US 
studies with a much larger professional base of practitioners than the UK. Three studies 
benefitted from larger sample sizes between 300 and over 600 participants, which likely 
increased the generalisability of findings (Martin et al., 2015; Dandachi-Fitzgerald et al., 
2013; Hirst et al., 2017).  
Response Rate 
Response rates were also variable throughout the studies, and it was not possible to 
report on response rates in some due to the sampling method utilised. Where reported, the 
mean response rate was 25%, with a range of 6 – 61%. 
Of the studies achieving only a small response rate, Dandachi-Fitzgerald et al. (2013) 
received the lowest with 6% from their survey distributed in Denmark. Additionally, Hirst et 
al. (2017) gained a 9% response rate. Studies with relatively larger response rates (between 
40-60%), included Young et al. (2016), Schroeder et al. (2016) and Slick et al. (2004), 
earning these studies higher scores on the CEBMa checklist. However, the majority of studies 
either did not report rates or had low response rates, and may reflect the opinions of only 
those motivated by the topic. 
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Measures 
All studies utilised self-report measures, which are at risk of bias due to social 
desirability. Furthermore, it is not clear from the majority of studies whether surveys were 
anonymous.  
None of the studies used standardised questionnaires with established validity and 
reliability due to the nature of the research being conducted. Eight papers based their 
questionnaires on other surveys that have yielded useful results which probably helped to 
increase the validity of their measures. However, the lack of standardised measures increased 
the risk of systematic bias. Brooks et al. (2016) suggested that unclear survey wording on one 
question had produced anomalous results. Similarly, the survey used by Barker-Collo and 
Fernando (2015) enabled respondents to select more than one response which made the 
findings unclear. For instance, it was not possible to discern whether respondents only used 
clinical judgement in assessment of effort or whether this was in conjunction with SPVTs. 
In addition, none of the studies investigated actual prevalence of SPVT use from 
reports or databases by employing a retrospective cohort design, and instead relied upon 
estimates.  
The majority of the surveys used only closed questions which limited the richness of 
findings compared to more open questions. For example, Young et al. (2016) neglected to 
explore practitioners’ reasons for using specific terminology over others, or other perceived 
reasons for SPVT failure, which would have been a valuable addition to the literature. 
Analyses 
The majority of studies employed only descriptive statistics to analyse their data. 
However, a substantial minority of more recent studies utilised inferential statistics to 
compare findings to that of previous studies (Hirst et al., 2017; Brooks et al., 2016; Schroeder 
et al., 2016; Young et al., 2016; Martin et al., 2015; Dandachi-Fitzgerald et al., 2013). Only 
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one study included confidence intervals (Mittenberg et al., 2002), increasing the likelihood of 
obtaining a ‘true’ value. 
Confounding Variables 
There appear to be some common potentially confounding variables throughout the 
studies. The first is related to the terminology used to describe performance and symptom 
validity. There was significant variability in terms used, and therefore in interpretations of 
meaning (unsurprising given this issue continues to be debated in the wider profession; 
Bigler, 2012). Whilst some studies explored the preferred terms used by practitioners, none 
investigated the respondents’ definitions of each term in their responses. Young et al. (2016) 
used ‘SVT’ to describe both symptom and performance validity tests. Furthermore, 
comparison of findings may have been impacted by the lack of consistency in the questions 
used across surveys, as terminology was not always identical. 
Some studies pooled data which made conclusions less clear. Young et al. (2016) 
combined stand-alone and embedded tests and Sharland and Gfeller (2007) pooled the base 
rates of invalid performance across practice settings, which may have led to an overall over-
estimation. Similarly, McCarter et al. (2009) failed to explore the proportion of litigation 
cases and forensic cases conducted by their sample, instead combining these practice settings. 
This is likely to have impacted findings due to the greater base rate of performance invalidity 
generally found in forensic settings.  
In addition, there were inconsistencies in reporting of the average number of 
assessments completed in the last year by respondents (reported in only half of the studies). 
Therefore, participants may have been responding based on limited or no contemporary 
experience conducting assessments. 
There were also inconsistencies in reporting of the average number of years of 
practice by respondents; although the majority of studies did report this. Barker-Collo and 
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Fernando (2015) noted that their sample of registered psychologists in general practice was 
likely to represent a highly diverse range of skills and experience. Varying levels of 
experience of practitioners was also reported by Martin et al. (2015), with half of their sample 
practicing in the field of neuropsychology for 10 years or less. Convenience sampling also 
meant that the credentials of the sample could not be verified in most cases. These factors 
may have decreased the likelihood of reaching the target population. 
Synthesis and Conclusions 
Taken together, findings were considered most convincing when there were adequate 
sample sizes and response rates, attempts to overcome selection bias and sophistication of 
analysis (as found in Hirst et al., 2017, and Dandachi-Fitzgerald et al., 2013).  
Generally, the literature lacked diversity in methods of investigating the topic, and this 
produced data limited by the quantitative designs used. There is currently no qualitative 
research into the beliefs of professionals regarding performance invalidity to the author’s 
knowledge. However, the samples employed in the studies under current review were 
generally representative of the target population, and findings were felt to be relevant and 
useful to practitioners in the field, holding limitations in mind. 
Concerning base rates of response invalidity, a substantial minority of forensic and 
medico-legal cases and a smaller minority of clinical assessments were considered by 
professionals to produce invalid performances across a range of geographical locations. 
Estimated base rates in clinical evaluations were between 3 and 10%, in forensic cases 
estimates were 17-25%, and were variable in litigation settings (between 8-30%). 
Concerningly, clinical judgement was relied upon by a vast proportion of respondents 
in the studies, despite established research indicating its limited reliability in detecting invalid 
performance (Faust et al., 1988).  
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Frequency of SPVT use was variable across evaluation setting, geographical location, 
and client characteristics. However, it appeared that over time the rate of SPVT use had 
increased, and validity testing recommendations had been more closely adhered to (Hirst et 
al. (2017).  
In terms of the most frequently used stand-alone PVT, the TOMM was the most 
prevalent across service settings. Embedded measures were also frequently used according to 
the studies in this review, particularly within the CVLT and Digit Span tests. 
The majority of professionals responding to the studies felt that SPVTs were 
mandatory in forensic settings, but not in clinical contexts. Justifications for excluding SPVTs 
were mostly related to belief that clinical cases rarely exaggerate and that symptom invalidity 
is obvious from other indicators, as well as time constraints. However, base rates reported by 
the studies reviewed also challenge the belief that SPVT failure is rare in clinical contexts. 
Reasons provided for using SPVTs were related to awareness of the literature and SPVTs 
being necessary to validate other findings. 
The majority of the samples encouraged examinees to do their best, but did not 
provide explicit warning, a practice more commonly found in forensic settings. Views were 
mixed on how to manage invalid performance, but most would administer additional SPVTs. 
When reporting on performance or symptom invalidity, the majority stated that the test results 
were invalid, inconsistent with the severity of the injury, and that no firm conclusions could 
be drawn. Very few participants across the studies used pejorative terms such as 
‘malingering’. 
Overall, there was variability in practitioners’ adherence to professional 
recommendations regarding performance and symptom invalidity, which is unsurprising 
given the relative recency of these guidelines and the supporting evidence base; although it 
appeared that the USA had progressed furthest in the field. This review would support the call 
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for further research into response validity outside of the USA (McMillan et al., 2009). 
Nevertheless, the surveys examined suggested a general trend towards consideration of this 
substantial and complex source of test data variance, both in research and clinical practice.  
Limitations and Future Directions 
In order to make efforts to access all relevant papers for inclusion in this review, 
various terminology and definitions of performance invalidity have been included and 
findings grouped, which may pose a threat to the validity of conclusions. However, this is 
reflective of the interchangeable use of terms in the literature and emphasises the need for 
clearer definitions of this concept in future research. It is also acknowledged that the use of a 
survey-specific quality appraisal tool may have acted to focus the critique on survey design 
rather than other issues such as the quality and interpretation of the results. 
In terms of clinical implications, the presence of out-dated and inaccurate beliefs and 
practices regarding validity testing by professionals suggests a need for more training as well 
as clearer and more consistent guidance from international professional bodies. It is also 
clinically implicated for professionals to keep more abreast of the literature to inform their 
practice. The current review suggests there is a need for clinicians to understand the 
contributing factors and mechanisms underlying SPVT failure and to consider this as part of a 
comprehensive biopsychosocial formulation. Broader research and clinical implications of 
the review are outlined in Appendix D. 
Despite considerable research, there remain unanswered questions within the field, 
particularly the mechanisms underlying invalid performance. Moreover, further research is 
required into the base rates of SPVT failure across treatment settings and geographical 
locations, as the current literature is predominantly from North America using mostly 
litigating and forensic populations. 
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The majority of the studies reviewed suffered from low response rates. It may be 
beneficial for future studies to offer incentives to respondents, or to utilise an alternative 
study design such as focus groups or exit polls. Qualitative research would also provide 
richer information on the more complex and subtle factors associated with performance 
validity and clinicians’ beliefs in relation to these. 
Future research would benefit from being clearer in the definitions of performance 
invalidity utilised. In particular, an exploration into UK PVT and SVT failure rates would be 
fruitful, as well as the factors that influence these. 
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Abstract 
Objectives: Performance validity tests (PVTs) and symptom validity tests (SVTs) have been 
recommended by the British Psychological Society to assist clinicians in validating 
assessment data. The current study aimed to explore the base rate of PVT failure in an NHS 
neuropsychology service, a setting relatively unexplored. A secondary aim was to investigate 
the relationship between PVT and SVT performance. Lastly, group differences in those 
passing and failing PVTs were explored in terms of demographics, and psychological 
functioning. 
Method: Archival test data (N = 127) was drawn from an NHS outpatient neuropsychology 
service. Participants completed one stand-alone PVT (the Test of Memory Malingering 
[TOMM]), one embedded PVT (Digit Span age-corrected scaled score [DS-SS]), and one 
SVT (the Personality Assessment Inventory [PAI]). 
Results: The base rate of failure on any one PVT was 18%. The rate of TOMM failure was 
12% and 4% additionally failed an embedded PVT. A significant relationship was found 
between PVT and SVT performance. Significantly elevated Paranoia, Anxiety-Related 
Disorders, and Schizophrenia PAI scales, as well as lower Full Scale IQ scores, were found in 
those who failed PVTs compared to those who passed. No other group differences on 
demographics were found, including reported financial incentive. 
Conclusions: Findings suggest that PVT failure occurs in a sizable minority of NHS 
outpatients with acquired brain injuries (ABI), which is unlikely to be simply explained by 
malingering for financial gain. Elevations in reported psychopathological symptoms may be 
related to emotional and cognitive sequalae resulting from the ABI itself. Careful 
interpretation of neuropsychological test data is endorsed. 
Key words: Performance validity, symptom validity, Test of Memory Malingering, 
Personality Assessment Inventory, neuropsychological assessment 
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Response Validity and Psychological Functioning in a UK NHS  
Acquired Brain Injury Sample 
The practice of neuropsychology rests upon the assumption that brain functioning can 
be inferred from neuropsychological test performance (Schoenberg & Scott, 2011). The 
reliability and validity of conclusions drawn is dependent on a number of factors. These 
include examinee characteristics and influences, such as whether they try their best. The 
assessment of examinee ‘effort’ is concerned with capturing non-neurological dimensions of 
performance (Bigler, 2012) and has gained increased attention in the field since the turn of 
the century (Carone & Bush, 2013). Clinical judgement has been shown to be an unreliable 
method of identifying validity issues (Faust, Hart, Guilmette & Arkes, 1988). Research has 
therefore focused on the empirical testing of this construct.  
The terminology used in the literature has varied widely (Larrabee, 2012); see 
Appendix A. In the current thesis, performance validity testing (PVT) will refer to the 
assessment of validity of performance on cognitive tasks, and symptom validity testing 
(SVT) will refer to the assessment of the validity of self-reported symptoms, consistent with 
Larrabee’s (2012) recommendations. PVTs are usually within the format of a forced choice 
memory paradigm that appears difficult to examinees but actually involves very easy 
recognition memory tasks. They should be affected very little by brain trauma, age, overall 
intellectual functioning, and education (Carone & Bush, 2013). Below-chance performance is 
considered to indicate malingering. Scores below cut-off based upon normative data are 
suggestive of invalid responding, without implying intent to feign (Slick, Sherman & Iverson, 
1999). SVTs are concerned with the degree to which symptomatic complaint on self-report 
measures is reflective of true symptoms, and are usually in the form of mood or personality 
inventories such as the Personality Assessment Inventory (PAI; Morey, 1991, 2007). As well 
as ‘stand-alone’ tests that have been specifically designed to evaluate performance or 
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symptom validity, the use of ‘embedded’ measures within existing tests can be used to 
identify invalid responding without increasing testing time. Several position papers have been 
released by professional bodies in both the USA and UK endorsing the routine use of validity 
tests in both clinical and forensic settings (Bush et al., 2005; McMillan et al., 2009). 
Knowledge of the prevalence or ‘base rate’ of invalid responding in the population of 
interest is necessary for meaningful interpretation of performance (Crawford, 2003). 
Historically, invalid performance in neuropsychological evaluation has been assumed to be 
rare outside of medico-legal contexts (McCarter et al., 2009). However, research is 
increasingly suggestive of a far greater prevalence of underperformance across clinical as 
well as forensic settings (Bush et al., 2005). Hampson, Kemp, Coughlan, Moulin and Bhakta 
(2014) found that 27% of a National Health Service (NHS) sample of acquired brain injury 
(ABI) patients failed one PVT. Similarly, Bunnage, Eichinger, Pearce, Duckworth, and 
Newson (2008) found a base rate of PVT failure of 26% in a non-litigating NHS sample. This 
points to the potential oversight of a substantial source of variance, contributing to inaccurate 
conclusions regarding neuropsychological functioning. This has been highlighted by Fox 
(2011) who found that failure of just one PVT eliminated the correlation between 
neuropsychological test performance and brain injury severity. 
Likely due to the lack of base rate data in UK clinical settings, clinicians continue to 
rely on clinical judgement in their interpretation of performance validity. McCarter, Walton, 
Brooks, and Powell (2009) found that only 5% of their sample of UK psychologists 
considered PVTs to be mandatory in clinical settings. Almost one third of the sample believed 
that invalid responding is obvious from observations or other test results.  
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Theories of Invalid Performance 
The malingering hypothesis. Validity test failure has been extensively shown to be 
predicted by the provision of financial gain by means of litigation (Binder & Rohling, 1996). 
A meta-analysis by Iverson (2005) found that the overall effect of malingering on 
neuropsychological test scores was considerably higher than the effect of brain injury, 
depression, and benzodiazepine withdrawal. The literature is less clear, however, on 
explanations of malingering in the absence of financial incentive, where it might be assumed 
that there would no motivation to underperform. Suhr, Tranel, Wefel, and Barrash (1997) 
found that validity test failure was not found to be predicted by litigation status in a mixed 
sample with diagnoses of ABI, depression, or somatization disorders. 
The cognitive impairment hypothesis. PVTs are designed to be insensitive to 
cognitive impairment and intelligence level, except in the presence of intellectual disabilities 
or significant neurodegenerative illness such as dementia (Demakis, Gervais, & Rohling, 
2008; Tombaugh, 1996). However, the literature continues to link significantly lower Full 
Scale IQ (FSIQ) with PVT failure. Hampson et al. (2014) found a greater base rate of PVT 
failure to be associated with greater injury severity in various NHS ABI populations 
suggesting that PVTs may be measuring genuine impairment. However, some authors have 
attributed this effect to the presence of malingered neuropsychological impairment 
(Constantinou, Bauer, Ashendorf, Fisher, & McCaffrey, 2005). The risk of type I error, 
whereby invalid responding is falsely identified, and type II error, whereby invalid results are 
taken as valid, greatly depends upon the sensitivity and specificity of the PVTs employed. 
The multivariate failure model (Larrabee, 2003) was proposed to address poor sensitivity 
rates, whereby failure on two or more PVTs can be understood as indicating invalid 
responding. This has received support in the literature (Victor et al., 2009).  
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Psychogenic hypotheses. PVTs are designed to be insensitive to mood disturbance 
(Carone & Bush, 2005). A meta-analysis by Veiel (1997) reported to find major cognitive 
impairment in depression; however, none of the studies utilised PVTs. When these findings 
were re-analysed, there was no difference in performance across depressed or non-depressed 
groups when performance validity was accounted for (Rohling, Green, Allen & Iverson, 
2002). Nevertheless, a relationship has been found between depressive symptomatology and 
levels of negative self-representation on SVTs (Morey, 2007).  
Whilst there lacked consistent support for a linear relationship between affective 
distress and PVT failure in the literature (Ashendorf, Constantinou & McCaffrey, 2004), there 
appeared to be an interaction between elevated psychological symptom reporting and PVT 
underperformance (Dandachi-Fitzgerald et al., 2011). Sumanti, Boone, Savodnik and 
Gorsuch (2005) found elevations on Personality Assessment Inventory (PAI; Morey, 1991, 
2007) scales pertaining to Somatic Complaints, Depression, Anxiety, Anxiety-Related 
Disorders and Schizophrenia in those failing PVTs compared to those who passed. Likewise, 
in their mixed clinical and litigating US sample, Whiteside et al. (2010) found significant 
associations between PVT failure and elevations on the PAI Somatic Complaints scale 
(specifically the Conversion subscale), with Schizophrenia, Anxiety, and Depression scales 
trending toward significance. Bigler (2012) has argued that unconscious processes such as a 
‘cry for help’, diagnosis threat, or distorted expectations (for example, the impact of disability 
status or other labels on identity) may offer useful information in understanding the 
mechanisms underlying invalid performance. Research into diagnosis threat has demonstrated 
that cognitive test performance and perceived influence of symptoms on performance are 
influenced by performance expectations (Suhr & Gunstad, 2005). Bigler (2012) suggests that 
PVTs are no more immune to these effects than other cognitive tests, and that perception of 
‘illness’ and related psychological state may explain ‘near-pass’, or above chance-level, PVT 
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performance. Indeed, the British Psychological Society (BPS) has warned clinicians to take 
care not to reinforce iatrogenic symptoms that may have developed through exposure to the 
disabled role or ill-health beliefs during the process of pursuing litigation or seeking 
treatment (McMillan et al., 2009). 
It has also been argued that elevated psychological symptom reporting and PVT 
failure simply represent consistent exaggeration across assessment modalities (Haggerty, 
Frazier, Busch, & Naugle, 2007). There lacks consensus on whether PVTs and SVTs measure 
similar or different constructs. Van Dyke, Millis, Axelrod, and Hanks (2013) found that the 
domains were not consistently invalidated, and therefore endorsed the separate assessment of 
performance and symptom validity. However, Whiteside, Dunbar-Mayer, and Waters (2009) 
found correlations between PVT failure and SVT failure using the Personality Assessment 
Inventory validity scales (PAI; Morey, 1991, 2007). The authors further demonstrated that 
SVT performance could significantly predict PVT performance and argued for the presence 
of a ‘defensive’ response style (Gaasedelen, Whiteside & Basso, 2017).  
Study Aims 
The current study aimed to explore the base rate of PVT failure in a sample of NHS 
outpatients with acquired brain injuries. Larrabee’s (2003, 2014) two-or-more-fails criterion 
will be applied to reduce the risk of type I error, which would add a novel element to the UK 
literature on performance validity. Furthermore, the BPS has highlighted the need for better 
understanding of the meaningfulness of PVT failure (McMillan et al., 2009). Without this, 
service-users could be subject to false positive diagnoses of suboptimal effort and associated 
invalid recommendations, and even incorrect social entitlements or legal verdicts (Mossman, 
Wygant & Gervais, 2012).  
Secondly, this study aimed to investigate whether PVTs tend to be failed when SVT 
indicators are elevated, or whether they measure different domains of response. Exploration 
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into the relationships between cognitive and psychological functioning has been identified as 
requiring continued research to inform clinical practice (Whiteside et al., 2010). A third aim 
was to explore differences between individuals who pass and fail PVTs in terms of 
psychological functioning and personality traits as measured by the PAI. This poses a 
significant addition to the literature, since very few studies have investigated response 
validity using clinical samples, and to the researcher’s knowledge none have explored the 
relationship with the PAI in the UK. Furthermore, group differences will be explored in 
relation to demographic variables, including potential financial incentive.  
Hypotheses 
It was hypothesised that base rates of failure on a single PVT would be approximately 
10-15% based on previous research using mixed clinical samples (Whiteside et al., 2010). 
The base rate of multiple PVT failure was anticipated to be around 5%.  
It was also hypothesised that a greater level of PVT failure would be found in 
participants with elevated PAI validity scales (Negative Impression Management and 
Infrequency scales), based on the North American literature (Whiteside et al., 2009; 
Gaasedelen et al., 2017).  
Due to previous findings endorsing a relationship between PVT failure and elevations 
on measures of emotional and personality functioning (Sumanti et al., 2005; Whiteside et al., 
2010), it was hypothesised that there would be significant positive relationships between PVT 
failure and the PAI scales, specifically Somatic Complaints, Depression, Anxiety, Anxiety-
Related Disorders, and Schizophrenia. A second analysis would be performed on the 
subscales of any PAI clinical scales found to be significantly related to PVT performance.  
Significant group differences were not anticipated for the demographic variables (age, 
diagnosis category, employment status, gender, and pre-morbid IQ [PMIQ]). However, it was 
anticipated that PVT failure would be associated with lower Full Scale IQ (FSIQ) and also 
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greater identification of potential financial incentive, based on previous findings (Hampson et 
al., 2014; Bianchini, Curtis, & Greve, 2006). 
As well as PVT pass and fail groups, TOMM pass or failure will be separately 
analysed in order to provide comparison to previous research findings utilising this measure 
(Whiteside et al., 2009, 2010).  
Method 
Participants 
Participants were drawn from consecutive referrals presenting to an NHS 
neuropsychology service in an urban setting in the South of England between February 2009 
and March 2014. The service supported people with acquired neurological conditions referred 
from a number of regional sources. Participants attended an outpatient programme of 
assessment, treatment, or both. Referral criteria required that all service-users had capacity to 
consent to the assessment, which was assessed by the treating clinician. 
Inclusion criteria were kept purposefully broad in line with the naturalistic design of 
the research, which aimed to recruit a sample representative of adults accessing NHS 
neuropsychology services in the UK. All participants were adults (aged 18 and over). The 
upper bound was set at 89 years since this is the lowest upper age limit of the measures 
included in the analysis. 
Exclusion criteria for the current study were a prior diagnosis of intellectual 
disability, and progressive neurological disorder, such as multiple sclerosis or dementia. This 
was due to literature suggesting these populations are more likely to score below cut-off on 
PVTs (Boone & Lu, 1999) (excluded n=21). Participants were also excluded if more than 
50% of their test data was missing (n=14).  
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Table 1  
Participant Characteristics 
 Descriptives 
Demographic n M SD 
Age 127 43.32 14.37 
Time since injury (months) 124 56.30 94.47 
PMIQ 119 104.52a 11.37 
FSIQ 117 99.14a 17.26 
 n %  
Gender 
   Male 
   Female 
127 
84 
43 
100 
66 
34 
 
Diagnosis 
   CVA/Stroke/AVM 
   Tumour/cancer related 
   mTBI 
   modTBI 
   sevTBI 
   TBI severity unknown 
   Hypoxia 
   Encephalitis 
   Infection/viral 
   Epilepsy related 
   Cyst 
127 
37 
22 
17 
30 
5 
2 
5 
4 
2 
2 
1 
100 
29 
17 
13 
24 
4 
2 
4 
3 
2 
2 
1 
 
Identified financial incentive 
   Yes 
   No 
122 
27 
95 
96 
21 
75 
 
Employment status 
   Employed 
   Unemployed 
127 
37 
90 
100 
29 
71 
 
Note. PMIQ = pre-morbid IQ; FSIQ = Full Scale IQ; CVA = cerebral vascular accident; AVM 
= arteriovenous malformation; mTBI = mild traumatic brain injury; modTBI = moderate 
traumatic brain injury; sevTBI = severe traumatic brain injury 
a PMIQ and FSIQ values represent mean rank scores and not IQ scores 
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The final sample (N=127) consisted of male (n=43) and female (n=84) participants 
ranging in age at assessment from 18 to 74 years (M=43.32, SD=14.37). Participants 
presented with a range of acquired brain injuries (see Table 1). 
The time since injury ranged from 1 to 545 months (M=56.30, SD=94.46). The 
majority of the sample indicated they were not in employment at the time of assessment 
(n=90). Furthermore, the presence of potential financial incentive was identified in 21% of 
the sample at the time of assessment (n=27). Potential financial incentive was routinely 
explored in the service during the clinical interview and included factors such as pursuing a 
compensation claim related to their ABI, or pursuing benefits such as disability living 
allowance, Personal Independence Payment, Employment and Support Allowance, Criminal 
Injuries Compensation Authority, or early retirement. Participants were not considered to be 
incentivised if their compensation claim had settled previously. It is acknowledged that this 
data may reflect self-report bias, and there could be many other types of incentive in this 
sample. For example, psychosocial incentives could include care elicited from others, or 
access to services.  
Since participants’ years of education was not available, a measure of PMIQ was 
utilised to indicate participants’ long-standing intellectual functioning. An updated PMIQ 
functioning measure became available to the department in 2011. Therefore, 43% (n=55) of 
participants completed the Wechsler Test of Adult Reading (Wechsler, 2001) and 56% (n=72) 
completed the Test of Premorbid Functioning (Wechsler, 2011). Both of these measures 
involve an oral reading task suggested to remain relatively unaffected by brain injury 
(Brooks, Holdnack, & Iverson, 2011). Both have also been extensively validated for use with 
ABI populations (Green et al., 2008; Franzen, Burgess, & Smith-Seemiller, 1997). Analysis 
was completed to explore whether the PMIQ test used had any impact on performance 
validity; Chi-square tests for independence (with Yates Continuity Correction) indicated no 
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significant relationships. PMIQ scores were therefore combined across the sample and ranged 
from 62 to 129 (M=104.52, SD=11.37).  
It was unfortunately not possible to gather data on participants’ ethnicities. However, 
according to the equality information pertaining to outpatient activity published by the Trust 
(2014), key ethnic groups included White British (32%), White Other (12%), Black (10%), 
Asian (10%), Other (4%), Mixed (1%), and ‘no data’ (28%).   
Power analyses were informed by previous research by Whiteside et al. (2009) and 
Whiteside et al. (2010) comparing PAI and TOMM performance in a US sample. Effect sizes 
ranged from rs = -.15 to .32 (small to medium effect; Cohen, 1992). Using the “G*Power 3” 
programme (Faul, Erdfelder, Lang, & Buchner, 2007), an allocation ratio of 0.18 was set to 
account for the estimated base rate of PVT failure (specifying alpha at 5% and desired power 
at 80%). The required total sample size to detect significant group differences on at least one 
PAI scale was estimated at 68.  
Measures 
The Personality Assessment Inventory (Morey, 1991, 2007). The PAI is a self-
reported inventory designed to assess various domains of adult personality and 
psychopathology, comprised of 344 items which load onto 22 non-overlapping scales. These 
include four validity indices (Positive Impression Management, Negative Impression 
Management, Inconsistency, and Infrequency), and 11 clinical scales (Somatic Complaints, 
Anxiety, Anxiety Related Disorders, Depression, Mania, Paranoia, Schizophrenia, Borderline 
Features, Antisocial Features, Alcohol Problems, and Drug Problems), each with three to four 
subscales. Additionally, there are five treatment consideration scales (Aggression, Suicidal 
Ideation, Non-support, Stress and Treatment Rejection), as well as two interpersonal scales 
(Dominance and Warmth). Respondents are required to indicate the extent to which an item 
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applies to them using a four-point scale ranging from ‘false’ to ‘very true’. Further details can 
be found in Appendix F. 
The PAI has been found to possess sound psychometric properties. Good test retest 
reliability has been demonstrated (Boyle & Lennon, 1994; Rogers, Flores, Ustad, & Sewell, 
1995), as well as adequate internal consistency and reliability (Morey, 1991). The PAI has 
been validated for use with ABI populations (Demakis et al., 2007).  
Cognitive performance validity tests. The current study will utilise two PVTs; one 
stand-alone measure (the TOMM; Tombaugh, 1996) and one embedded measure (Digit Span 
age-corrected scaled score [DS-SS], from the Wechsler Adult Intelligence Scale-III/IV; 
Wechsler, 1997, 2010). These two PVTs are endorsed by the BPS (McMillan et al., 2009) and 
are among the most commonly utilised in UK practice (McCarter et al., 2009). Furthermore, 
these measures operate across a variety of cognitive modalities (visual and auditory memory), 
in line with BPS recommendations (McMillan, 2009).  
The Test of Memory Malingering (Tombaugh, 1996). The TOMM is a 50-item visual 
memory test designed to discriminate between genuine memory impairment and ‘malingered’ 
memory deficits. Individuals complete two learning trials and a supplementary retention trial. 
Tombaugh (1996) suggests a cut-off of 45 out of a possible 50 on Trial 2 to indicate 
suboptimal performance. The TOMM has demonstrated good specificity and sensitivity 
(Tombaugh, 1996, 1997; Haber & Fichtenberg, 2006), as well as good internal consistency, 
reliability, and convergent validity (Moore & Donders, 2004). Furthermore, the TOMM has 
been found to be relatively insensitive to affective distress (Boone, 2007).  
Digit Span age-corrected scaled score (DS-SS). The DS-SS is an embedded PVT 
within the Working Memory Index of the Wechsler Adult Intelligence Scale-III/IV 
(Wechsler, 1997, 2010), whereby individuals are required to repeat increasing strings of 
numbers in the same order, reverse order, and in sequence. Axelrod, Fichtenberg, Millis, and 
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Wertheimer (2006) found improved specificity and sensitivity when using a scaled score 
Digit Span cut-off of five or less in their sample referred for neuropsychological assessment, 
in comparison to utilising the historically more popular Reliable Digit Span (Greiffenstein, 
Baker, & Gola, 1994). They noted that this cut-off minimizes false positive errors and 
achieves a “73% probability in support of a diagnosis of response bias” (p. 521). 
An updated version of this measure was utilised by the service during the period 
sampled (the Digit Span subtest from the WAIS-III and WAIS-IV; Wechsler, 1997, 2011). It 
was decided to pool data using both versions based upon previous research suggesting that 
the Digit Span subtest in both versions is highly correlated (Robbins, 2014). Furthermore, 
analyses were conducted to explore group differences relating to the test version used. No 
significant associations between PVT performance and the version used were found. 
Design and Procedure 
With permission of the host Trust, two research assistants were briefed on the project 
and collated raw archival neuropsychological test data from patient archives. Archival files 
were available from 2009 until the clinic was discontinued in 2014. This data was 
anonymised at the point of entry onto a password-protected database through the use of 
participant numbers and stored securely on an encrypted USB. Data was cleaned and 
quantitatively analysed by the researcher, and kept in a secure location. A between-subjects 
design was used to investigate group differences; no variables were manipulated. Data will be 
retained securely for ten years in line with University regulations. 
The service employed a comprehensive neuropsychological assessment using a fixed-
battery approach, administered in a fixed order for all participants over two days across two 
consecutive weeks. Although the dataset was relatively complete due to the use of a fixed 
battery approach, the number of participants included in analyses addressing each research 
question varied somewhat due to missing data points for some cases. Pairwise deletion was 
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employed in correlational analyses.   
Ethical Considerations 
Ethical approval was granted by the NHS REC Proportionate Review Service for the 
use of anonymous archival data, which was made available by the Trust and nevertheless 
stored securely in line with university regulations. It was not possible for any individual 
participant to be identified according to their test data. No risks for participants were 
identified. The archival database was also partly accessed as part of a separate thesis project; 
ethics applications, analyses and write-up were completed independently (Appendix I 
provides further information). Presentation of findings to the neuropsychology department 
within the NHS Trust involved has been planned following completion of the project. 
Results 
Analysis was run to assess distribution of data using IBM’s Statistical Package for the 
Social Sciences (SPSS), version 24. Since none of the performance validity variables were 
determined to be normally distributed and unequal group sizes were expected, non-parametric 
equivalents were utilised throughout.  
The skewness and kurtosis of performance validity variables were examined in order 
to identify outliers in the data which were then verified to identify any error in data entry. 
Base Rates of PVT failure 
Analysis was conducted with Trial 2 of the TOMM using a cut-off of 45 based on the 
manual recommendations (Tombaugh, 1996). An age-corrected scaled score of five or below 
on Digit Span was used as a cut-off based on recommendations in the literature for achieving 
optimal sensitivity and specificity (Axelrod et al., 2006).  
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Table 2 
PVT Failure Base Rates 
 n Number of fails Base rate (%) 
Failure of TOMM 
Failure of DS-SS 
Failure of ≥1 PVT* 
Failure of 2 PVTs 
127 
91 
127 
91 
15 
12 
23 
4 
12 
13 
18 
4 
Note. PVT = Performance validity test; TOMM = Test of Memory Malingering; DS-SS = 
Digit Span age-corrected scaled sore 
* Failure of TOMM and DS-SS includes participants failing both PVTs, i.e. 11 failed TOMM 
only, 8 failed DS-SS only, and 4 failed both, therefore 23 failed ≥1 PVT.   
 
Table 2 presents the PVT failure rate according to cut-offs and group comparisons of 
interest. As hypothesised, a small minority failed two PVTs (TOMM and DS-SS; 4%). The 
rate of TOMM failure (12%) was consistent with the hypothesis and previous findings 
(Whiteside et al., 2010), but the base rate of failure on any one PVT was somewhat greater 
than expected (TOMM or DS-SS; 18%). 
Since there were only four participants in the ‘two PVT fails’ group, the analysis was 
conducted using a ‘one or more PVT fails’ group, or essentially PVT pass versus failure. 
Group differences were analysed in order to ensure that the one or more PVT fails group was 
not significantly skewed by the inclusion of the two PVT fails group. 
Bonferroni adjustments were utilised throughout all analyses. Although when applied 
strictly the significance should be smaller than the critical p value, the result was considered 
significant if it was equal to or smaller than the critical p value. This was decided in an effort 
to reduce the likelihood of type II errors, since Bonferroni adjustments are considered a 
highly conservative method when applied to a high number of comparisons (Napierala, 
2012). 
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Demographics Effects 
Initial exploratory analyses were employed to examine the demographic variables for 
significant associations across the groups (PVT pass or fail, and TOMM pass or fail) and the 
PAI variables using Chi-square tests for independence1, or Mann Whitney U tests to explore 
differences in group means. A Bonferroni correction was applied; the new familywise error 
rate to detect statistical significance was p≤.025.  
Table 3 shows that there were no significant differences in mean age across the PVT 
pass or fail groups, or the TOMM pass or fail groups. Chi-square tests for independence and 
Mann-Whitney U tests revealed no significant relationships between the PVT or TOMM pass 
or fail groups in relation to diagnosis category, time since injury, presence of identified 
financial incentive, or employment status. Furthermore, there were no significant 
relationships found across the TOMM groups in relation to gender. A significant relationship 
was found between the PVT pass and fail groups, and gender (χ2 (1, N = 127) = 5.19, p=.023, 
phi = -.22). However, examination of crosstabulation indicated there was no meaningful 
gender difference found in the group of interest (PVT fail group).  
Mann-Whitney U tests showed no significant differences across the PVT and TOMM 
pass and fail groups in terms of PMIQ. Finally, differences in current FSIQ across groups 
were explored using Mann-Whitney U tests. A significant difference was found in FSIQ 
scores between the PVT pass and fail groups. A significantly lower IQ score was found in the 
PVT fails group (Mdn = 89, n =22) in comparison to the pass group (Mdn = 100, n = 95), U = 
637, z = -4.04, p<.000, r = -.37 (medium effect). FSIQ was also significantly lower in the 
TOMM fail group (Mdn = 89, n = 14) compared to the TOMM pass group (Mdn = 100, n = 
103), U = 356, z = -3.07, p=.002, r = -.28 (medium effect).  
                                                             
1 With Yates Continuity Correction 
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Table 4 presents a small number of statistically significant relationships between the 
demographic variables and the PAI variables after Bonferroni corrections (the new 
familywise error rate for the validity scales was p≤.013 and p≤.003 for the clinical scales). 
Gender was found to be significantly related to Antisocial score, with males scoring higher 
(M = 54.29, SD = 11.23, n =83) than females (M = 47.93, SD = 6.88, n = 40), r = .28, n = 
123, p=.002. Age was significantly inversely correlated with Borderline score (r = -.29, 
p=.001) and Aggression score (r = -.31, p=.001). Time since injury was positively correlated 
with Negative Impression Management score (r = .26, p=.005). 
Interestingly, there were a number of significant inverse relationships found between 
PMIQ score and the PAI variables, namely the Inconsistency scale (r = -.34, p<.000), Somatic 
Complaints (r = -.30, p = .001), Anxiety-Related Disorders (r = -.36, p<.000), Paranoia (r = -
.28, p=.002), Borderline (r = -.31, p=.001), Antisocial (r = -.33, p<.000), Drug Problems (r = 
-.39, p<.000) and Aggression scores (r = -.30, p=.001). Furthermore, a number of significant 
inverse correlations were found between current FSIQ score and the PAI variables; including 
Inconsistency (r = -.34, p<.000), Somatic Complaints (r = -.32, p=.001), Anxiety-Related 
Disorders (r = -.32, p=.001), Drug Problems (r = -.37, p<.000) and Suicidality scales (r = -
.30, p=.001). 
In summary, initial analysis indicated no significant relationships between the 
demographic variables and PVT or TOMM groups, with the exception of current FSIQ. There 
were a small number of statistically significant correlations with the PAI variables, and FSIQ 
was significantly related to Inconsistency, Somatic Complaints, Anxiety-Related Disorders, 
Drug Problems and Suicidality scores. Given the overall lack of significant associations 
between the demographic variables and the performance validity variables, overall analysis 
utilising the entire sample was deemed appropriate. 
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Table 3 
Demographic Effects for the PVT Variables 
 
Demographic variable p  
 PVT pass or fail TOMM pass or fail 
A    Gender .023* .160 
B    Age .385 .609 
C    Diagnosis .808 .235 
D    Time since injury .084 .048 
E    Financial incentive .836 .509 
F    Employment status .401 1.000 
G    PMIQ .037 .144 
H    FSIQ .000* .002* 
*Significant at the p≤.025 level after Bonferroni corrections 
 
Table 4 
Demographic Effects for the PAI Variables 
 
 p  
 PAI validity scales (p<.013) PAI clinical scales (p<.003) 
 INC INF NIM PIM SOM ANX ARD DEP MAN PAR SCZ BOR ANT ALC DRG AGG SUI STR NON RXR DOM WAR 
A .319 .987 .696 .837 .018 .125 .124 .041 .570 .744 .770 .259 .002* .012 .967 .157 .107 .041 .126 .018 .545 .084 
B .826 .771 .027 .081 .823 .198 .067 .121 .011 .003 .243 .001* .009 .981 .833 .001* .188 .084 .171 .077 .686 .250 
C .254 .314 .342 .637 .542 .378 .483 .062 .706 .539 .301 .532 .181 .607 .172 .254 .183 .563 .292 .132 .169 .574 
D .481 .283 .005* .531 .049 .899 .576 .418 .521 .125 .104 .632 .984 .758 .331 .543 .205 .257 .512 .059 .043 .273 
E .795 .865 .043 .119 .065 .753 .900 .096 .233 .526 .414 .247 .032 .497 .146 .320 .749 .318 .907 .694 .378 .706 
F .012 .693 .386 .717 .240 .514 .909 .646 .613 .561 .747 .996 .947 .712 .251 .492 .117 .184 .503 .793 .667 .590 
G .000* .261 .014 .233 .001* .003 .000* .015 .056 .002* .055 .001* .000* .631 .000* .001* .046 .062 .445 .057 .365 .226 
H .000* .058 .004 .949 .001* .018 .001* .134 .171 .020 .090 .027 .084 .940 .000* .049 .001* .109 .220 .215 .958 .989 
Note. A = gender; B = age; C = diagnosis category; D = time since injury; E = financial incentive; F = employment status; G = pre-morbid IQ; H = Full Scale IQ 
PAI validity scales: INC = Inconsistency; INF = Infrequency; NIM = Negative Impression Management; PIM = Positive Impression Management  
PAI clinical scales: SOM = Somatic Complaints; ANX = Anxiety; ARD = Anxiety-Related Disorders; DEP = Depression; MAN = Mania; PAR = Paranoia; SCZ = 
Schizophrenia; BOR = Borderline; ANT = Antisocial; ALC = Alcohol Problems; DRG = Drug Problems; AGG = Aggression; SUI = Suicide; STR = Stress; NON = Non-
support; RXR = Treatment Rejection; DOM = Dominance; WAR = Warmth 
*Validity scales significant at the p≤.013 and clinical scales significant at the p≤.003 level after Bonferroni corrections 
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Performance Validity and Symptom Validity 
It was hypothesised that significant associations would be found between elevations 
on certain PAI validity scales (Negative Impression Management and Infrequency scales) and 
PVT failure (PVT pass and fail, and TOMM pass and fail groups). Spearman’s correlation 
coefficients were calculated in order to identify significant relationships between the 
variables (Table 5).  
After Bonferroni corrections (the new error rate was p≤.012), results showed a 
medium positive correlation between PVT performance and the Negative Impression 
Management scale (rs = .34, n = 123, p<.000), with high scores associated with PVT fails. 
There was a significant positive relationship between Infrequency and PVT performance 
before Bonferroni corrections but not after, therefore this scale may be considered to be 
trending towards significance. 
 
Table 5 
Correlations between PVT Performance (Pass and One or More Fails) and SVT Performance 
 PAI validity scales 
 INC INF NIM PIM 
Correlation coefficient .10 .19 .34* -.17 
Sig. (2-tailed) .294 .039 .000 .063 
n 121 123 123 123 
Note: INC = Inconsistency; INF = Infrequency; NIM = Negative Impression Management; 
PIM = Positive Impression Management 
*significant at the p≤.012 level after Bonferroni corrections 
 
To investigate group differences in SVT performance, Mann-Whitney tests were 
utilised with PVT pass or fail as the grouping variable (see Table 6). A Bonferroni correction 
was applied; the new rate for significance was p≤.012. A significant difference was found in 
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Negative Impression Management scores between the PVT pass and fail groups. A Mann-
Whitney test revealed that scores were significantly higher in the PVT fail group (Mdn = 66, 
n = 20) than the pass group (Mdn = 55, n = 103), U = 754.0, z = -3.80, p<.000, r = .34 
(medium effect; Cohen, 1992). Before Bonferroni corrections, Infrequency scores were 
significantly higher in the PVT fails group compared to the pass group. However, this result 
did not hold when adjusting for multiple comparisons. 
The hypothesis was partially supported; Negative Impression Management scores 
were significantly higher in the one or more PVT fails group compared to PVT pass group, 
but there were no significant differences held in Infrequency scores after Bonferroni 
adjustments. 
To demonstrate that this result was not being driven by the multiple PVT fails cases, 
the analysis was re-run exploring the PVT pass and one PVT fail groups. The same effect was 
found; Negative Impression Management scores were significantly higher in the one fail 
group (Mdn = 66, n = 17) than the pass group (Mdn = 55, n = 103); U = 716.5, z = -3.19, 
p=.001, r = -.29. 
Since the bivariate statistical analyses (Spearman’s correlation) and test of difference 
(Mann Whitney U) generated highly similar results, the test of difference analysis will be 
reported only for the remaining analysis. 
Mann-Whitney tests were utilised with TOMM performance (pass or fail) as the 
grouping variable (see Table 6). Consistent with the PVT group, a significant difference was 
found in Negative Impression Management scores between TOMM pass and fail groups after 
Bonferroni corrections (the new familywise error rate was p≤.012). Negative Impression 
Management scores were significantly higher in the TOMM fail group (Mdn = 66, n = 13) 
than the TOMM pass group (Mdn = 55, n = 110), U = 368.0, z = -2.87, p=.004, r = .26 (small 
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to medium effect). There were no other significant group differences on any of the other PAI 
validity scales. 
The hypothesis that Negative Impression Management would be significantly higher 
in the TOMM fail group compared to TOMM pass was supported. However, there were no 
significant differences in Infrequency scores across the groups.  
 
Table 6 
Group Comparisons for the SVT Variables (PAI Validity Scales) 
 
   PAI validity scales 
 
   INC INF NIM PIM 
PVT pass/fail groups 
 Mann-Whitney U 1190.0 1047.5 754.0 1080.0 
 Z -1.05 -2.06 -3.80 -1.86 
 Sig. (2-tailed) 
 
.292 .039 .000* .063 
TOMM pass/fail groups 
 Mann-Whitney U 678.5 613.5 368 607 
 Z -.20 -.84 -2.87 -.89 
 Sig. (2-tailed) .844 .400 .004* .373 
Note: INC = Inconsistency; INF = Infrequency; NIM = Negative Impression Management; 
PIM = Positive Impression Management 
*significant at the p≤.012 level after Bonferroni corrections 
 
Performance Validity, Personality and Psychological Functioning 
It was hypothesised that significant associations would be found between PVT failure 
and elevations on Somatic Complaints, Depression, Anxiety, Anxiety-Related Disorders, and 
Schizophrenia PAI scales.  
Mann-Whitney U tests were used with PVT pass or fail as the grouping variable (see 
Table 7). After Bonferroni corrections (the new error rate was p≤.003), significant differences 
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were found in Schizophrenia, Anxiety-Related Disorders, and Paranoia scores between PVT 
pass and fail groups. Schizophrenia scores were significantly higher in the PVT fail group 
(Mdn = 63.5, n = 20) than the pass group (Mdn = 55, n = 104), U = 804.0, z = -3.54, p<.000, 
r = -.32 (medium effect). Similarly, Anxiety-Related Disorders scores were significantly 
higher in the PVT fail group (Mdn = 59.5, n = 20) than the pass group (Mdn = 53.5, n = 104), 
U = 887.5, z = -3.05, p=.002, r = -.27 (small to medium effect). Paranoia scores were also 
higher in the fails group (Mdn = 56.5, n = 20) than the pass group (Mdn = 50, n = 104), U = 
908.5, z = -2.93, p=.003, r = -.26 (small to medium effect). Before Bonferroni corrections, 
Somatic Complaints, Anxiety, Depression, Borderline, Suicidality, Non-Support, Treatment 
Rejection and Warmth scores were significantly higher in the PVT fails group compared to 
the pass group.  
Again, the analysis was re-run exploring the pass and one PVT fail group to explore 
the effect of the two PVT fails cases. Mann-Whitney U tests showed that scores were 
significantly higher in the one fail group compared to the pass group for Schizophrenia (U = 
759.0, z = -2.95, p=.003, r = -.27), Paranoia (U = 824.0, z = -2.54, p=.011, r = -.23), and 
Anxiety-Related Disorders (U = 832.5, z = -2.48, p=.013, r = -.23). However, only 
Schizophrenia scores remained significant following Bonferroni corrections, suggesting the 
two fails cases had some impact on the Paranoia and Anxiety-Related Disorders scores in the 
analysis. 
Exploratory post-hoc Mann-Whitney U tests utilizing the subscales from the PAI 
scales found to be significantly related to PVT failure (Anxiety-Related Disorders, Paranoia 
and Schizophrenia) were then run. The Anxiety-Related Disorders scale is comprised of 
Obsessive Compulsive Disorder, Phobias, and Traumatic Stress subscales, the Paranoia scale 
includes Hypervigilance, Persecution, and Resentment subscales, and finally the 
Schizophrenia scale contains Paranoia, Social Detachment, and Thought Disorder subscales. 
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Utilising the new familywise error rate of p≤.006, only Paranoia-Hypervigilance 
scores were significantly higher in the one or more PVT fails group (Mdn = 57, n = 11) than 
the pass group (Mdn = 48, n = 57); U = 261.0, z = -2.81, p=.005, r = -.34 (medium effect).  
The hypothesis was partially supported; Anxiety-Related Disorders and Schizophrenia 
scores were significantly higher in the one or more PVT fails group compared to the pass 
group, but there were no significant differences held in Somatic Complaints, Depression or 
Anxiety scores after Bonferroni adjustments. In addition, significantly higher Paranoia scores 
were found in the PVT fails group compared to the pass group. Furthermore, it was found 
that the Paranoia-Hypervigilance subscale specifically was greater in the PVT fail group than 
the pass. However, there were no other significant subscale group differences after 
adjustments for multiple comparisons. 
To explore TOMM performance and the PAI clinical scales, Mann-Whitney tests were 
utilised, with TOMM pass or fail as the grouping variable (see Table 7). In contrast to the 
analysis of PVT performance, no significant differences were found in the PAI clinical scale 
scores between TOMM pass and fail groups after Bonferroni corrections (p≤.003). Before 
adjustments for multiple comparisons, significantly higher Anxiety, Anxiety-Related 
Disorders, Depression, Schizophrenia, and Suicidality scores were found in the TOMM fail 
group in comparison to the pass group. Therefore, there appeared to be a trend in the data 
consistent with previous research (Whiteside et al., 2010). Trending subscales were analysed 
exploratively to see whether there were any group differences. Mann-Whitney U tests showed 
that no scores were significantly higher in the one or more PVT fails group in comparison to 
the pass group.
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Table 7 
Group Comparisons for the SVT Variables (PAI Clinical, Treatment Consideration and Interpersonal Scales) 
 
 PAI scales 
 
Group SOM ANX ARD DEP MAN PAR SCZ BOR ANT ALC DRG AGG SUI STR NON RXR DOM WAR 
 
PVT pass or fail groups 
 
 Mann-Whitney U 1026.0 940.5 887.5 918.5 1398.0 908.5 804.0 944.5 1317.0 1193.5 1281.5 1200.0 992.5 1097.5 968.5 1041.5 1295.5 1042.0 
 Z -2.24 -2.74 -3.05 -2.87 -0.07 -2.93 -3.54 -2.72 -0.46 -1.19 -0.68 -1.15 -2.38 -1.61 -2.52 -2.09 -0.59 -2.08 
 Sig. (2-tailed) .025 .006 .002* .004 .944 .003* .000* .007 .646 .232 .498 .250 .017 .108 .012 .037 .557 .037 
 
TOMM pass or fail groups 
 
 Mann-Whitney U 532.0 362.0 380.0 386.0 624.0 472.0 395.0 490.5 502.5 464.0 666.5 622.0 413.0 663.0 586.0 517.5 659.0 539.5 
 Z -1.38 -2.81 -2.67 -2.62 -0.60 -1.89 -2.54 -1.73 -1.59 -1.93 -0.19 -0.57 -2.36 -0.17 -0.88 -1.46 -0.26 -1.28 
 Sig. (2-tailed) .167 .005 .008 .009 .546 .059 .011 .083 .112 .054 .846 .568 .018 .867 .378 .143 .798 .202 
 
 
Note. SOM = Somatic Complaints; ANX = Anxiety; ARD = Anxiety-Related Disorders; DEP = Depression; MAN = Mania; PAR = Paranoia; 
SCZ = Schizophrenia; BOR = Borderline; ANT = Antisocial; ALC = Alcohol Problems; DRG = Drug Problems; AGG = Aggression; SUI = 
Suicide; STR = Stress; NON = Non-support; RXR = Treatment Rejection; DOM = Dominance; WAR = Warmth 
*significant at the adjusted p≤.003 level  
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Finally, a hierarchical regression was utilised to explore whether PVT performance 
could be predicted by SVT performance (Negative Impression Management), or elevated 
psychopathological scales (Schizophrenia, Anxiety-Related Disorders and Paranoia). 
Preliminary analyses were conducted to check for violations of the assumptions of linearity, 
homoscedasticity, and unrestricted range. The assumption of normality of residuals may have 
been violated. It was decided to proceed on balance that findings are not usually vulnerable to 
effects of small deviations from normality (Tabachnick & Fidell, 2007); however, results 
should be interpreted with caution. 
 
Table 8 
Hierarchical Regression Model Predicting PVT Performance 
 
 PVT performance 
Predictor R² ΔR² β F p 
Step 1 .095 .095  12.22 .001** 
   NIM   .308  .001** 
 
Step 2 
 
.122 
 
.027 
  
3.96 
 
.005* 
   SCZ   .126  .305 
   ARD   .003  .983 
   PAR   .158  .262 
Note. NIM = Negative Impression Management; SCZ = Schizophrenia; ARD = Anxiety-
Related Disorders; PAR = Paranoia 
*p < .01, **p < .001 
 
Negative Impression Management was entered at Step 1 explaining 9.5% of the 
variance in PVT performance (F (1, 117) = 12.22, p<.001). After entry of the Schizophrenia, 
Anxiety-Related Disorders, and Paranoia scales at Step 2 the total variance explained by the 
model as a whole was 12.2%, F (3, 114) = 3.96, p<.005. Only Negative Impression 
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Management made a unique significant contribution (β = .308, p<.001), with Schizophrenia, 
Anxiety-Related Disorders and Paranoia explaining an additional 2.7% of variance. This was 
a non-significant contribution, R2 change = .027, F change (3, 114) = 1.184, p=.319.  
Discussion 
Base Rates of PVT Failure 
The base rates of PVT failure found were in support of the hypotheses; TOMM failure 
was found in 12% of the sample, and 4% failed both PVTs. However, the rate of one or more 
failures on any PVT (TOMM or DS-SS) exceeded expectations and was in fact 18%. 
Bunnage et al. (2008) and Hampson et al. (2014) found base rates of PVT failure as high as 
26% and 27% respectively in their NHS ABI samples using the Word Memory Test (Green, 
2003). This is also an interesting finding considering a survey of UK neuropsychologists 
found that just 16% utilised PVTs in their clinical practice, believing base rates of PVT 
failure in clinical cases to be low (McCarter et al., 2009). 
Demographics Effects 
There were few relationships or group differences found in terms of PVT and PAI 
performance on the demographic variables. This is in support of the hypothesis and in line 
with previous research (Armistead-Jehle, 2010). 
There were no significant relationships found between the demographic variables and 
performance validity, with the exception of current FSIQ; PVT failure was associated with 
significantly lower current FSIQ. This could be due to the PVTs used being sensitive to 
cognitive impairment, as suggested by Hampson et al. (2014). Alternatively, the result could 
be understood as consistent underperforming on both PVTs and other cognitive tests, 
including the measure of FSIQ.  
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There were a small number of statistically significant correlations with the PAI 
variables; males scored higher on the Antisocial scale than females, and younger participants 
scored higher on the Borderline and Aggression scales than older. These findings are 
unsurprising given young males are generally found to exhibit more disinhibited and 
aggressive behaviours (Dumais et al., 2005). In addition, participants with lower PMIQs 
scored higher on a number of PAI scales in comparison to higher PMIQ. Lower current FSIQ 
scores were similarly related to higher psychopathology scores. This may indicate a greater 
vulnerability to mental distress in those with lower cognitive functioning, which is supported 
by the intellectual disabilities literature (Smiley, 2005). Finally, a positive relationship was 
found between Negative Impression Management and the time since injury, which could be 
suggestive of a ‘cry for help’ related to chronicity of problematic brain injury sequalae. 
The hypothesis that the PVT failure rate would be increased where financial incentive 
had been identified was not supported by the data; no group differences were found, 
consistent with Suhr et al. (1997). This is a highly interesting finding as previous research has 
focused on malingering as an explanation for PVT failure (Bianchini et al., 2006). This 
hypothesis cannot be ruled out due to the possibility of other psychosocial incentives 
operating, for example, time off work, or access to services. However, the inclusion of this 
variable in the current study nevertheless presents a novel addition to the literature and 
provides some information regarding certain types of external incentives.  
Performance Validity and Symptom Validity 
Both PVT and TOMM failure groups were found to be significantly associated with 
higher scores on the Negative Impression Management scale of the PAI. This finding 
supports the view that elevations on this scale can be expected in individuals performing 
below threshold on PVTs, and that PVTs and SVTs are related, consistent with Whiteside et 
al. (2009) and Haggerty et al. (2007). However, the effect size for group differences between 
RESPONSE VALIDITY AND PSYCHOLOGICAL FUNCTIONING 
72 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
TOMM performance and Negative Impression Management in the current study was slightly 
smaller than Whiteside and colleagues (2009).  
Although the PAI Infrequency scale has previously been found to be related to PVT 
failure (Whiteside et al., 2009), this was not supported in the current study and could be 
attributable to differences in sample characteristics. There were no significant associations 
found between the other PAI validity scales (Positive Impression Management and 
Inconsistency) and PVT failure. This may suggest exaggeration of difficulties in the PVT fail 
group, since there were no indications of validity threats otherwise.  
These findings endorse elevated SVT performance as a useful indicator for risk of 
cognitive PVT failure. Likewise, PVT failure may indicate exaggerated responding on SVTs. 
However, it is suggested that neither PVTs nor SVTs can provide comprehensive information 
pertaining to the intentions and motivations underlying test-taking behaviour, and that 
evaluation of both domains remains valuable in contributing to a comprehensive 
biopsychosocial formulation (McMillan et al., 2009).  
Performance Validity, Personality and Psychological Functioning 
For the PVT failure group, the hypothesis was partially supported; Anxiety-Related 
Disorders and Schizophrenia scores were significantly higher in participants who failed any 
one PVT in comparison to the pass group. Furthermore, Paranoia scores were found to be 
higher in the PVT fail group compared to pass, which had not been expected based on 
previous research. Analysis of subscales revealed that Paranoia-Hypervigilance scores were 
driving this group difference. This is partially consistent with the findings of Sumanti et al. 
(2005) who showed that PVT failures were related to elevated scores on PAI Somatic 
Complaints, Depression, Anxiety, Anxiety-Related Disorders, and Schizophrenia scales in a 
psychiatric sample. 
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It was further found that only Negative Impression Management was able to 
significantly predict PVT performance; none of the PAI clinical scales made significant 
contributions to the predictive model. However, findings should be interpreted with caution 
due to potential violation of the assumption of normality of residuals. 
In contrast, no significant differences were found in the expected PAI clinical scales 
between TOMM pass and fail groups. Nevertheless, before adjustments for multiple 
comparisons, the Depression, Anxiety, Anxiety-Related Disorders, Schizophrenia and 
Suicidality scales appeared to be trending towards significance. This is comparable to the 
findings of Whiteside et al. (2010) in their US study utilising the TOMM. Furthermore, it was 
found that there were no significant differences in terms of subscale scores between the 
groups. This suggested that the significant group differences on Anxiety-Related Disorders, 
Schizophrenia, and Paranoia (Hypervigilance) in the PVT analysis were driven by Digit Span 
performance rather than TOMM performance. It may be that Digit Span suffers from weaker 
sensitivity and specificity; however, the elevated PAI scales generally concur with other 
findings in the literature, which decreases the likelihood that significant findings are the result 
of type I error. 
Although significant relationships were found between PVT failure and self-reported 
psychological symptoms, it is not possible to infer the causality of PVT failure. However, 
since Negative Impression Management was the only validity scale significantly related to 
PVT performance, and was the only significant unique predictor of PVT performance, on 
balance it seems likely that scale elevations were subject to at least some level of symptom 
exaggeration. It is unclear why these scales would be subject to a greater level of 
exaggeration than others; Appendix F can be referred to for the PAI items comprising each 
scale and subscale. Negative impression management could also be understood in the context 
of the experience of stigma and shame following brain injury (Hagger & Riley, 2017). Nochi 
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(1998) explored the impact of undergoing neuropsychological assessment on the self-image 
of TBI survivors and argued that ongoing complications, such as litigation, can result in 
adjustment difficulties and feelings of helplessness and persecution. The author suggested 
that the assessment process can provide opportunity for individuals to communicate and 
legitimise their struggles. It may be that the less visible, non-physical consequences of ABI, 
which may have been tapped by the PAI, create a need for individuals to communicate a 
more negative impression to professionals in order to get their needs met. In addition, it could 
be hypothesised that impression management requires a level of performance monitoring that 
may be impaired following ABI, and particularly in frontal lobe injuries (Rabinowitz & 
Levin, 2014). 
It could be argued that some of the items included on the Anxiety-Related Disorders, 
Schizophrenia and Paranoia scales are related to brain injury sequalae or cognitive 
impairment. For example, within the Anxiety-Related Disorders scale, ‘I have impulses that I 
fight to keep under control’ could be understood as relating to problems with disinhibition 
rather than OCD. The items within the Traumatic Stress subscale may relate to sustaining the 
brain injury itself and ongoing difficulties in this population, for example, ‘I can’t seem to get 
over some things from my past’. Elevations on the Phobia subscale may have been due to 
indirect consequences of the ABI, for example, ‘I don’t mind driving on freeways’. 
Furthermore, the Schizophrenia scale could be considered to tap into cognitive or social 
difficulties arising from brain trauma, for example ‘My thinking has become confused’, and 
‘I just don’t seem to relate to people very well’. Items on the Paranoia scale are themed 
around Hypervigilance, Persecution and Resentment. Social and interpersonal difficulties 
such as irritability, and poor social communication and social problem-solving skills are 
common after brain injury (Schoenberg & Scott, 2011). It could be that the group who 
performed more poorly on validity tests were experiencing a greater level of these difficulties 
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or adjustment difficulties in comparison to those who performed well. Till, Christensen and 
Green (2009) explored the use of the PAI with ABI populations and similarly found a number 
of transdiagnostic items on the Schizophrenia, Depression, and Somatic Complaints scales, 
noting items related to “anti-social behaviours, history of substance abuse and psychiatric 
problems of an anxiety-related and paranoid nature” (p. 663). The authors concluded that 
high levels of psychopathology and personality disturbance are often found on measures used 
with individuals with ABIs, but that this may be attributable to the cognitive and physical 
sequelae of the injury rather than representing psychiatric disorder. It is also acknowledged 
that there exists a high prevalence of comorbidity in ABI populations (Rogers & Read, 2007). 
The current study supports the use of caution when interpreting elevations on the 
Schizophrenia scale when using the PAI with individuals with acquired brain injuries (Morey, 
2003), and additionally endorses the careful interpretation of elevations on the Anxiety-
Related Disorders and Paranoia scales.  
This explanation may be corroborated by the finding that the median FSIQ score was 
11 points lower in the PVT failure group compared to the pass group (taking the fail group 
into the ‘low average’ IQ category from the ‘average’ category). Since PMIQ scores were 
comparable across the PVT pass and fail groups, it seemed more likely that the result was due 
to cognitive impairment arising from the brain injury, or secondary to higher levels of 
exaggeration.  
The lack of relationship between PVT performance and somatic preoccupation in the 
current study is puzzling since somatization has historically been found to be the most 
consistently elevated scale in those performing poorly on PVTs (Sumanti et al., 2005; Boone 
& Lu, 1999; Whiteside et al., 2010). This finding refutes the idea that motivation during 
neuropsychological assessment is mediated by understanding and response to physiological 
symptoms (Whiteside et al., 2010; Boone & Lu, 2010). It may be that PVTs in the current 
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study tapped a construct other than motivation, such as complex cognitive or 
neuropsychological sequalae resulting from brain injury. In addition, no significant elevations 
were found in depression and anxiety scores in this sample, suggesting that PVT failure is 
unlikely to be attributable to affective distress. This was consistent with previous findings 
(Ashendorf et al, 2004). Research suggesting that cognitive performance is dependent on the 
interaction between PVT failure and psychological symptomatology (Green, Rohling, Allen, 
& Iverson, 2001) may be applicable. The current findings may reflect an interaction of factors 
that underlie both neuropsychological test performance, psychological symptom reporting 
and ‘effort’ rather than linear, causal relationships.  
The findings also relate to the broader literature on experiences of neuropsychological 
assessments. Keady and Gilliard (2002) explored service-users’ experiences of dementia 
assessments and identified a high prevalence of anxiety and uncertainty. The authors argued 
that feelings of perceived threat, particularly in the context of poor rapport with the examiner, 
can lead to the adoption of coping strategies to create distance, such as defensiveness, 
confrontation, resistance, and passivity. This was found to be exacerbated by cognitive 
fatigue. Those struggling more with the cognitive, emotional and behavioural sequalae of 
brain injury, and particularly when insight into difficulties is high, may experience the 
assessment as particularly distressing (Paterson & Scott-Findlay, 2002). This may further 
contextualise performance. 
Knowledge of the base rate of PVT failure and relationship with psychological 
functioning in UK neuropsychology settings can offer clinicians a potentially useful tool in 
assessing the extent to which test performance can be confidently attributed to brain injury. 
Although PVT failure in itself cannot definitively identify invalid performance due to PVTs 
being imperfect measures, it could stimulate further and more nuanced exploration of an 
individual’s needs.  
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Limitations and Future Directions 
There are a number of limitations to be borne in mind when evaluating the 
conclusions of the present study. Firstly, the archival nature of the research limits 
experimental manipulation of variables and, therefore, no causal statements can be made. 
However, the benefits of using naturalistic clinical data lie in its ecological validity, and 
consequent generalisability to NHS neuropsychology practice. 
A further limitation concerns the lack of data regarding participants’ ethnicities, years 
of education, and English not being the first language; risk factors for PVT failure (Victor et 
al., 2009). Although the tests of pre-morbid functioning utilised have been validated for use 
with brain injury populations (Green et al., 2008; Franzen et al., 1997) these could also have 
been subject to biased responding. Future studies would likely benefit from gathering such 
demographic data. The pooling of PMIQ and FSIQ data based upon different tests and 
versions also presents an important limitation. However, analysis on the impact of the test or 
version suggested no significant effect on study variables.  
Despite the sample size being comparable to, and often exceeding, published 
literature in the field (Locke et al, 2008, Van Dyke et al., 2013), groups were unequal due to 
the nature of PVT failure. Fidelity to Larrabee’s criterion for detecting invalid responding 
was intended; however, the classification was relaxed from two or more PVT fails to any one 
PVT fail due to small numbers in the comparison group. This increased the likelihood of type 
I error. Potential misclassifications represent a pervasive challenge for all performance 
validity research (Hawes & Boccaccini, 2009). Furthermore, the current study was not 
concerned with malingering diagnosis per se, but rather with the meaning of PVT failure. It 
has been shown that when even one PVT is failed, the correlation between cognitive test 
performance and the documented brain injury is lost (Fox, 2011).  
RESPONSE VALIDITY AND PSYCHOLOGICAL FUNCTIONING 
78 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
The use of cut-off scores may pose a methodological problem in the current research; 
non-neurological test-taking behaviour is increasingly being considered to be on a continuum 
rather than a binary taxonomy (Bigler, 2012). Above-chance but below cut-off performance is 
potentially an important future direction for validity research, particularly in clinical settings. 
Additionally, more recently developed supplementary PAI scales such as the Malingering 
Index and Defensiveness Index (Morey, 2007) were not available in the current study but 
would pose valuable lines of enquiry in future research. 
It is hoped the current findings will inform UK psychologists in their clinical practice, 
and their decision to use PVTs, interpretation of test data, and wider biopsychosocial 
formulation. Research on this topic, as well as clinical practice, would benefit from 
continuing to explore the non-neurological factors influencing performance, rather than 
focussing on malingering in isolation. As Iverson and Binder (2000) propose, “the well-
informed clinician will seek to identify all variables that may affect symptom reporting or 
neuropsychological test performance and be careful not to over- or under-interpret evidence 
of negative response bias” (p. 853). It is also suggested that more patient-centred, qualitative 
lines of enquiry may be particularly informative in our understanding of patients’ needs and 
this complex construct.  
Conclusions 
This thesis endorses the view that PVT failure occurs in a sizable minority of NHS 
ABI patients, which is unlikely to be simply explained by malingering for financial gain. It is 
suggested that further exploration of interactions between psychogenic factors and validity 
test performance could reduce false positive diagnoses and associated invalid 
recommendations. Although the study is limited by methodological issues related to 
naturalistic design, within this design also lies its strengths. It is hoped that the findings will 
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be directly applicable to current NHS clinical neuropsychology practice, and contribute to the 
provision of comprehensive and valid assessments of those who use these services. 
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Appendix A 
Response Validity Terminology  
 
In the current thesis, the following terminology has been utilised, based upon definitions 
provided by Larrabee (2012), McMillan et al. (2009), Bush et al. (2005) and Bigler (2012); 
• Response validity – an umbrella term concerning the validity of responses (both 
performance and symptom responses); 
• Performance validity – the validity of performance on cognitive tasks; 
• Symptom validity – the validity of self-reported symptoms; 
• Effort – “Motivation to comply with implicit or explicit test instructions with regard to 
speed, accuracy or other performance requirement. Failure on a test of effort means that 
someone has performed poorly on the test (below a suitable cut-off or low absolute 
score), and where the test was appropriate for that person, that they performed below 
their capability as determined by other criteria” (BPS guidance; McMillan et al., 2009, p. 
18). “‘Failure’ reflects non-neurological factors that reduce neuropsychological test 
scores and invalidates findings” (Bigler, 2012, p. 632); 
• Malingering – “The intentional production of false or exaggerated symptoms, motivated 
by external incentives. Although symptom validity tests are commonly referred to as 
malingering tests, malingering is just one possible cause of invalid performance” (NAN 
Position Paper; Bush et al., 2005, p. 420); 
• Response bias – “An attempt to mislead the examiner through inaccurate or incomplete 
responses or effort” (NAN Position Paper; Bush et al., 2005, p. 420); 
• Dissimulation – “The falsification or misrepresentation of symptoms by over 
representation or under representation, with an intention to appear different from the 
‘true’ state” (BPS guidance; McMillan et al., 2009, p. 18). 
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Appendix B 
Summary Table of Included Studies (Section A) 
 
 
 
 
 
 
Study Design/Sample  
 
Base Rates of SPVT 
Failure 
 
Key Findings  
 
Clinical Use of SPVTs 
 
Beliefs Regarding  
SPVT Use 
 
Limitations 
Hirst et al. 
(2017) 
N = 654  
Licensed clinical 
psychologists with ≥100 
post-grad clinical 
neuropsychological 
assessment hours; 21% were 
board certified in 
neuropsychology 
Online survey emailed to 
National Academy of 
Neuropsychology (NAN) 
and International 
Neuropsychological Society 
(INS) members 
9% response rate 
Approximately half 
conducted assessments in 
secondary gain contexts 
such as forensic work, 
disability claimants, and VA 
hospitals 
Respondents who followed 
recommendations reported 
significantly higher base 
rates of probable poor 
effort (22% versus 18%, 
p=.008), definite poor 
effort (15% versus 10%, 
p<.001), probable 
malingering (10% versus 
7%, p=.002), & estimated 
base rates of definite 
malingering (7% versus 
5%, p=.028) than 
respondents who did not 
follow practice 
recommendations 
International psychologists adhere to NAN/AACN 
recommendations as well as US psychologists 
Clinicians working with paediatric and geriatric 
populations did not follow the guidance as closely 
as those working with adults 
More experienced neuropsychologists were less 
likely to adhere to guidance 
An average test battery included 6 embedded/stand-
alone SPVTs. Those who adhered to 
recommendations typically employed a 
significantly greater number of validity measures 
than those who did not adhere (average of 10 
measures compared to 5.8, p<.001) 
Majority of both US and international respondents 
indicated that they mostly or always encouraged 
examinees to give their best effort (91% and 88% 
respectively) 
US respondents were significantly less likely than 
non-US to provide explicit warning that effort tests 
would be used (22% and 32% respectively, p=.003) 
Sample was divided on whether to provide 
70% believed that an SPVT 
should be included in every 
assessment 
A greater proportion of less 
experienced respondents 
believed that every test battery 
should contain validity testing 
than more experienced 
respondents (78% and 62% 
respectively, p<.000) 
 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Despite aiming to 
investigate 
international 
adherence to 
guidelines, only 
17% of responses 
were international 
and survey was 
only disseminated 
in English 
Low response rate 
so may only reflect 
opinions of those 
motivated by the 
topic 
Failed to report 
average number of 
assessments 
conducted in the 
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Mean years of practice = 16 immediate feedback, as well on whether to 
discontinue the assessment if detecting suspect 
effort. Approximately one third indicated they 
mostly/always continued to interpret the assessment 
even when SPVTs had been failed 
last year 
 
Brooks, 
Ploetz, & 
Kirkwood 
(2016) 
N = 282 
Neuropsychologists working 
with children/adolescents in 
North America/Canada 
Online survey emailed via 
professional listservs, open 
for 8 weeks 
Mean years of practice = 12 
Majority conducted clinical 
assessments but a third also 
conducted forensic 
assessments 
Mean number of 
assessments performed 
yearly = 102 
Not reported Majority utilised clinical judgement methods; 92% 
endorsed behavioural observations of poor 
compliance, 90% endorsed discrepancies between 
records, self-report and observed behaviours 
92% used at least one stand-alone or PVT and 88% 
used at least one SVT per assessment, 60% used 
embedded validity tests. An average assessment 
included 1 stand-alone PVT, 1-2 embedded PVTs, 
and 1-2 embedded SVTs 
Number of validity tests used was not affected by 
clinicians’ level of training 
Those who conducted forensic assessments 
administered more SPVTs (Cohen’s d=.57) 
Most utilised stand-alone PVTs were the Test of 
Memory Malingering (TOMM), Medical Symptom 
Validity Test (MSVT), and Word Memory Test 
(WMT). Most utilised embedded PVTs were the 
Reliable Digit Span (RDS) & California Verbal 
Learning Test (CVLT). Most utilised SVTs were 
the Behavior Rating Inventory of Executive 
Function (BRIEF) validity indicators & Behavior 
Assessment System for Children-2 (BASC-2) 
validity indicators 
95% often/always encouraged examinees to give 
their best “effort”; 76% never/rarely warned 
examinees that tests are sensitive to exaggeration 
71% believed validity testing to 
be mandatory in forensic 
assessments, 53% believed 
should be mandatory in 
psychiatric facilities, half 
believed desirable in schools 
SPVTs felt to be possible to 
administer and not unnecessary 
in any setting 
76% utilised SPVTs due to 
research evidence, 68% in order 
to validate other test scores, 
64% due to own experience 
supporting use, & 18% due to 
third party instruction 
Not utilising SPVTs was most 
commonly due to difficulty in 
interpretation for very young 
children and children with 
severe cognitive impairment 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Potential sampling 
bias due to 
methodology; 
however, authors 
addressed by 
inviting views of 
both practitioners 
regularly using 
SPVTs and those 
who did not 
Insufficient 
responses gained 
for practitioners 
working with the 
youngest children 
(below five years), 
limiting 
generalisability 
Not possible to 
report response rate 
due to design 
Unclear survey 
wording may have 
produced 
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40% often/always reported that results were 
‘inconsistent with severity of condition’, and 93% 
never/rarely use the term ‘malingering’ 
anomalous results 
Schroeder, 
Martin, & 
Odland (2016) 
N = 24 
Online survey emailed to 
North American 
neuropsychologists/experts 
(defined as being first author 
on four recent papers 
regarding validity testing or 
participation in the AACN 
response validity 
conference) 
50% response rate  
92% conducted clinical 
assessments and 91% 
forensic assessments 
87% primarily evaluated 
adults and 12% worked 
across the lifespan 
Mean years of practice = 20 
Not reported Experts had similar beliefs and practices to non-
expert neuropsychologists in a prior study (Martin, 
Schroeder, & Odland, 2015) 
Respondents used a broad range of methods to 
identify suspect performance 
More than 90% of experts often/almost always used 
both stand-alone and embedded SPVTs  
Majority reported that in 95% of cases they gave 
more weight to SPVT results that their initial 
clinical judgement 
95% often/always encouraged examinees to try 
their best, and 25% often/always directly warn that 
tests are sensitive to poor effort 
If suspecting response invalidity, vast majority 
rarely/never directly confronted the examinee, and 
would not prematurely terminate the assessment  
47% would state that responses suggested 
‘malingering’ 
100% of experts considered 
validity testing to be mandatory 
in forensic examinations and 
65% felt SPVTs to be 
mandatory in clinical 
assessments 
Experts considered malingering 
to be the most likely cause of 
SPVT failure in forensic 
settings, but a very infrequent 
cause of failure in clinical 
settings 
Experts considered other 
factors, such as 
somatoform/conversion 
disorder, psychiatric issues or 
attitude towards testing 
(oppositional, non-compliant or 
indifferent behaviour), to be 
underlying SPVT failure in 
clinical contexts, although there 
was no consensus as to common 
underlying mechanisms 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Small sample 
Generalisability – 
only North 
American 
psychologists 
working with adult 
populations 
Failed to report 
average number of 
assessments 
conducted in the 
last year 
 
 
Young, Roper, 
& Arentsen 
(2016) 
N = 172 
US psychologists working 
with the Veterans Affairs 
healthcare system and likely 
practising neuropsychology 
Overall, 28% of examinees 
were estimated to fail 1 
PVT, 18% fail 2, and 13% 
fail 3 or more 
Mean estimated failure 
rates varied across 
settings; 23% in clinical 
Approximately two-thirds indicated that they used 
SPVTs always/frequently across clinical and 
forensic contexts 
When utilised, 89% employed 2 or more SPVTs  
There was no consensus regarding the use of 1 or 2 
Factors considered to limit 
SPVT use were time constraints, 
and influence of 
supervisors/organisations 
 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Unclear survey 
wording meant 
PVT and SVT use 
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Email survey, open for one 
month 
44% response rate 
43% conducted forensic 
assessments, & 16% board 
certified 
Mean number of 
assessments yearly = 155 
outpatients, 12% in 
inpatients, and 39% in 
disability exams 
Greater rate of failure 
estimated for mTBI and 
PTSD populations 
The less likely respondents 
were to use SPVTs, the 
lower their estimated base 
rates of failure 
Board certification status 
not associated with 
estimated PVT failure rates 
Base rates in VA system 
were comparable to other 
US medico-legal settings 
SPVT failures to indicate invalid performance (45% 
and 47% respectively) 
Respondents with a greater number of professional 
organisation memberships tended to employ more 
PVTs (p<.02); no correlation was found for board 
certification 
Stand-alone PVTs were used always/frequently 
63% of the time, embedded were used in 73% of 
cases, and SVTs utilised in 43% of cases 
The most commonly employed stand-alone PVTs 
were the TOMM, Rey-15 Item, and WMT. The 
most commonly employed embedded PVTs were 
the CVLT-II Forced Choice, RDS, Wisconsin Card 
Sorting Test (Failure to Maintain Set), and Digit 
Span Age-Corrected Scaled Score. The MMPI-2 
was the most utilised SVT 
Respondents were most likely to report on results as 
‘poor/suboptimal effort’. ‘Malingering’, ‘feigning’ 
and ‘disability seeking’ were the least popular 
descriptions 
was combined 
Failed to report 
number of years of 
practice of 
respondents 
 
 
 
Barker-Collo 
& Fernando 
(2015) 
N = 73 
Registered psychologists in 
New Zealand 
Advertised through NZ 
Psychological Society and 
NZ College of Clinical 
Psychology and provided 
weblink for online survey; 
open for 4 months 
89% of sample self-
Majority of respondents 
(32%) reported 5-20% of 
cases presented with 
suspect effort 
24% of sample reported 1-
5% of their cases present 
with suspect effort 
24% indicated suspect 
effort in 20-50% of 
examinees 
Majority of respondents (56%) assessed response 
validity in <50% of examinees 
75% reported using multiple methods to assess 
response validity 
Most utilised methods were clinical judgement 
(47%) and SVTs (38%), such as the MMPI and PAI 
When used, most popular stand-alone PVTs were 
the TOMM (39%), WMT (26%), and the Rey 15-
Item (28%) 
SPVTs were employed in 
secondary gain contexts or when 
clients presented with unusual 
symptoms/inconsistent history 
Respondents reported using 
SPVTs due to endorsement by 
professional boards, awareness 
of support in the literature, to 
safeguard the validity of 
conclusions drawn, and to 
improve client care 
High level of 
selection bias likely 
due to the sampling 
method and 
likelihood that 
respondents were 
highly motivated to 
take part 
Relatively small 
sample 
Not possible to 
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identified as clinical or 
educational psychologists 
and others were ‘generalists’ 
Mean years of practice = 14 
years 
Most respondents were 
clinicians working for the 
Accident Compensation 
Corporation (ACC) or 
privately; minority also 
conducted medico-legal 
assessments 
Reasons given for not assessing 
response validity included when 
the population/context was 
deemed inappropriate, as well as 
practical challenges such as time 
restraints, limited access to tests 
and lack of training/experience 
Respondents were also 
concerned with over-reliance on 
test scores, the notion that 
validity testing does not reveal 
underlying motivations, and 
disapproval of using deception 
with clients 
report response rate 
due to design 
Unstandardized 
survey  
Did not utilise 
inferential statistics 
Failed to report 
average number of 
assessments 
conducted in the 
last year 
Martin, 
Schroeder, & 
Odland (2015) 
N = 316 
Licensed North American 
neuropsychologists who 
primarily assess adults 
Online survey based on 
previous surveys, sent via 
professional 
neuropsychology email 
listservs and open for 
approximately 3 weeks 
Majority (33%) worked in 
private practice, and 73% of 
sample did at least some 
forensic assessments 
Mean years of practice = 12 
Not reported 92% often or always use embedded and stand-alone 
measures to assess response validity 
35% indicated that they most commonly use 2 or 
more PVT ‘failures’ to indicate cognitive invalidity 
13% reported they relied on clinical judgement, but 
89% agreed or strongly agreed that validity testing 
is more accurate than clinical judgement  
Respondents used mean of 1.6 stand-alone and 3.2 
embedded measures in clinical assessments and 2.4 
stand-alone and 3.9 embedded SPVTs in forensic 
evaluations 
Most commonly employed stand-alone SPVTs were 
the TOMM and WMT. RDS and the CVLT-2 were 
the most endorsed embedded SPVTs. Most utilised 
SVTs were the MMPI and PAI 
97% often/always encouraged examinees to try 
their best, and 38% often/always explicitly warned 
98% believed SPVTs to be 
mandatory in forensic settings 
and 55% mandatory in clinical 
settings 
SPVTs considered by majority 
to be more accurate than clinical 
judgement; forensic 
neuropsychologists significantly 
more likely to strongly hold this 
belief than clinical workers (p < 
.001) 
Most likely cause of test 
invalidity in clinical cases was 
believed to be psychiatric issues 
(not including somatoform or 
conversion disorder), and most 
likely cause in forensic settings 
was reported to be malingering 
Least common underlying 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
North America only 
– limited 
generalisability 
Not possible to 
report response rate 
due to design 
Failed to report 
average number of 
assessments 
conducted in the 
last year 
Experience was 
variable; majority 
of sample had 
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examinees that SPVTs would be utilised 
When suspecting invalid performance, majority 
would administer additional SPVTs and would not 
directly confront the examinee 
91% often/always reported that ‘test results are 
inconsistent with the severity of injury’. Majority 
(74%) used the term PVT, and just 11% preferred 
‘malingering’  
causes in both clinical and 
forensic settings were 
considered to be genuine 
cognitive impairment, and 
stereotype/diagnosis threat 
Respondents who read more 
SPVT literature considered 
validity testing to be 
significantly more valuable than 
those who read less (p<.001), 
and were significantly more 
likely to strongly agree that 
PVTs are more accurate than 
clinical judgement (p<.001) 
practiced in 
neuropsychology 
for 10 years or less 
 
 
Allcott et al. 
(2014) 
N = 73 
UK multi-disciplinary 
experts at consultant level in 
medico-legal settings 
(psychologists, psychiatrists, 
orthopaedic specialists, 
neurologists, & occupational 
therapists) 
Emailed to members of the 
Directory of Expert 
Witnesses as well as other 
known experts; open for 6 
months 
25% response rate 
70% of respondents 
indicated that three 
quarters of examinees 
were ‘genuine’, and 25% 
considered half of their 
cases to be ‘disingenuous’ 
Majority (49%) relied upon discrepancies between 
self-reports and medical history to assess response 
validity 
44% of respondents reported they did not routinely 
administer SPVTs 
40% of respondents did not standardly express 
opinion on the validity of performance and 11% 
reported they had never considered performance 
validity 
25% believed ‘malingering’ to 
be a medical diagnosis 
55% of their UK sample were 
not able to list any peer-
reviewed literature on the 
subject, and half of respondents 
who indicated they routinely use 
PVTs could not name any peer-
reviewed research 
Noted scepticism in relation to 
validity testing in qualitative 
comments, e.g. “history and 
examination are the best 
indicators” 
46% felt it was desirable to 
know the amount of 
compensation being claimed 
when forming an opinion. 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Relatively small 
sample 
Did not utilise 
inferential statistics 
Failed to report 
average number of 
assessments 
conducted in the 
last year 
Failed to report 
number of years of 
practice of 
respondents 
 
98 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
Dandachi-
Fitzgerald, 
Ponds, & 
Merten (2013) 
N = 515 
Surveyed 6 European 
countries (Germany, Italy, 
Denmark, Finland, Norway, 
Netherlands) 
Email survey sent to chairs 
of each of the European 
Societies of 
Neuropsychology to forward 
to respective members; six 
of 12 societies agreed to 
participate 
Survey open for 18 months 
Range of 6-25% response 
rates  
96% psychologists, 3% 
physicians 
95% conducted clinical 
assessments, 55% undertook 
forensic work 
Mean years of practice = 10 
Median assessments 
conducted in previous year = 
70 
 
Base rates of insufficient 
effort estimated to be 10% 
in clinical assessments & 
15% in forensic 
assessments 
Malingering was thought 
to occur in 4% of their 
clinical cases and 10% of 
forensic cases 
Discrepancy was found 
between general estimated 
base rates of malingering 
and respondents’ estimates 
of base rates in their own 
practice (general estimates 
were rated as 10% in 
clinical and 20% in 
forensic assessments) 
69% of respondents reported they often/always base 
their judgements on qualitative methods such as 
discrepancies between self-reports, records, and 
condition severity 
Only 11% indicated systematically using SPVTs in 
clinical assessments, and just 44% in forensic 
assessments across the whole sample 
Respondents in Norway were most likely to use 
SPVTs (86% in the majority of the forensic 
assessments and 54% in the majority of clinical 
assessments) 
Respondents in Italy reported the lowest rate of 
SPVT use (13% and 10% in the majority of 
forensic and clinical assessments respectively) 
When used, the most popular stand-alone PVTs 
were the Amsterdam Short-Term Memory Test, 
Rey 15-Item, and the TOMM. The most commonly 
utilised embedded PVTs was the Rey Auditory 
Verbal Learning Test (however, >50% of 
respondents indicated never utilising embedded 
tests) 
Respondents were divided on whether they warn 
examinees about SPVT use; however, most 
encouraged examinees to give their best effort 
If suspecting poor effort, majority would continue 
the assessment and encourage the examinee to give 
good effort, but were divided on administering 
additional SPVTs or directly confronting the 
examinee 
66% indicated they would often/always state that 
test results are ‘inconsistent with severity of injury’, 
Majority believed could rely on 
clinical judgement to assess 
response validity 
Reasons provided for not 
utilising SPVTs included 
presence of severe cognitive 
impairment (47%), poor effort 
being obvious in the pattern of 
other test scores (25%), and 
poor effort being rare in clinical 
settings and therefore validity 
testing is unnecessary (23%) 
Reasons provided for using 
SPVTs were related to having 
read the literature (63%), 
SPVTs being necessary to 
validate other findings (59%) 
and in line with 
recommendations from 
professional bodies (59%). 31% 
of respondents endorsed using 
SPVTs to “cover my back” 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Representativeness 
of Western 
European 
neuropsychologists 
limited due to only 
6 of 12 countries 
responding  
Some low response 
rates e.g. 6% in 
Denmark 
Broad sampling 
method increased 
the risk of non-
response bias, as 
not all of the 
participants 
approached would 
have conducted 
neuropsychological 
assessments. No 
method of 
discerning to what 
extent non-response 
bias affected 
findings 
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& 60% would indicate that ‘no firm conclusions 
can be drawn’ 
McCarter, 
Walton, 
Brooks, & 
Powell (2009) 
N = 130 
UK survey emailed to 
members of the BPS 
Division of 
Neuropsychology 
22% response rate  
70% of sample conducted 
both clinical and forensic 
assessments, 29% solely 
clinical and 1% solely 
forensic 
 
5-7% of clinical cases 
were estimated to require 
validity assessment, and 
60% of medico-legal 
assessments were 
considered to require 
SPVT on a mandatory 
basis 
16% of respondents in clinical settings used SPVTs 
the majority of the time, compared to 73% in 
medico-legal settings 
Clinicians working in medico-legal settings were 
more likely to always comment on test taking 
behaviour than those in clinical settings (95% and 
76% respectively) 
However, SPVTs were employed standardly by 
59% in medico-legal assessments and only 11% of 
clinical assessments; majority in clinical settings 
utilised SPVTs in fewer than 5% of cases  
The TOMM was most popular in both clinical 
(32%) and medico-legal work (58%).The WMT 
was utilised by 34% of medico-legal workers but 
none of the clinical workers. The Rey 15-Item was 
also used by a sizeable minority (15%) 
Most popular embedded measures were 
comparisons of recognition memory and free recall 
scores in clinical assessments (8%), and Raven’s 
Progressive Matrices in medico-legal work (8%). 
However, 11% reported using their own 
idiosyncratic methods 
SVTs were employed by a minority of medico-legal 
workers but very rarely in clinical settings 
60% of medicolegal workers 
considered SPVT use to be 
mandatory in legal cases, 
compared to 5% in clinical 
settings. 16% of clinical 
workers considered SPVTs to be 
‘unnecessary’, and majority 
(55%) indicated PVTs were 
‘optional’ 
Justifications given for validity 
testing included endorsement by 
scientific/professional literature, 
and need to validate the 
assessment findings overall  
Most commonly endorsed 
reason for not including PVTs 
was related to the belief that 
invalid responding is obvious 
from observations or other test 
results (29%) 
Respondents also reported time 
constraints and perception of 
low base rates of malingering in 
clinical cases as justifications 
for the exclusion of SPVTs in 
assessments 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Failed to report 
years of practice or 
number of 
assessments 
undertaken yearly  
Failed to explore 
proportion of 
clinical and 
forensic work by 
sample 
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Sharland & 
Gfeller (2007) 
N = 188 
Paper surveys mailed to a 
random sample of 
approximately one third of 
NAN professional members 
(clinical neuropsychologists) 
26% response rate 
Mean years of practice = 17 
30% board certified in 
neuropsychology 
Unknown practice settings 
or proportion of 
clinical/forensic assessments 
conducted 
In their own practice, 
median base rate of 
probable insufficient effort 
was 10%, and definite 
insufficient effort was 
rated at 5% 
In general practice, median 
base rate of deliberate 
exaggeration in medico-
legal assessments was 
20%, and in cases with no 
obvious secondary gain 
estimates were 5% 
Ranges of base rates were 
‘considerable’ (0-90%) 
56% of respondents reported they often/always 
included an SPVT 
Most utilised method of assessing response validity 
was to compare severity of cognitive impairment 
with severity of the condition (88% often/always) 
63% often/always relied upon stand-alone PVTs, 
46% often/always used embedded measures, and 
55% often/always utilised SVTs 
The TOMM and the Rey-15 were the most utilised 
stand-alone PVTs. The CVLT and RDS were the 
most frequently used embedded PVTs. The MMPI-
2 was the most utilised SVT 
89% often/always provided encouragement to 
examinees to try their best 
22% often/always warned that tests are sensitive to 
effort, but 52% never/rarely provide warning 
Respondents most commonly reported that ‘test 
results were inconsistent with the severity of the 
injury’, and least likely to report that ‘test results 
suggest or indicate malingering’ 
Participants had the greatest 
confidence in the TOMM; 
classification accuracy was 
rated at 7.5/10 
 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Failed to report 
years of practice or 
number of 
assessments 
conducted in past 
year 
Lower than desired 
response rate 
Failed to report 
practice settings or 
proportion of 
clinical/forensic 
assessments 
conducted  
 
 
Boccaccini, 
Boothby, & 
Overduin 
(2006) 
 
N = 116 
Pain specialists and clinical-
forensic psychologists 
working in personal injury 
medico-legal settings 
Mailed questionnaire 
(including a vignette 
describing an attorney-
referred case) to members of 
Not reported 71% indicated that they assess the validity of pain 
complaints, and this was comparable across pain 
specialists (68%), forensic specialists (74%), and 
forensic-pain specialists (76%) 
Most popular method was to review collateral 
information, such as reports of other professionals 
and medical records, observations of pain-related 
behaviours and discrepancies between pain 
complaints and test data 
Qualitative comments by 
respondents without forensic 
training appeared to dispute the 
necessity of validating pain 
symptoms e.g. ‘diagnostic tests 
are not as useful for pain 
conditions as other medical 
problems’ 
Relatively low 
response rate 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Failed to report 
respondents’ 
number of years of 
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the American Pain Society, 
and relevant divisions of the 
American Psychological 
Association 
Asked respondents whether 
they would attempt to assess 
response validity, and 
methods they would use 
18% response rate 
34% had specialised training 
in forensic and pain 
assessment 
29% reported they would use SVTs. The most 
commonly endorsed SVT was the MMPI-2 (56% of 
clinicians trained in forensic and pain assessment). 
The TOMM was endorsed by a minority of 
respondents and these tended to be forensic 
specialists 
No respondents endorsed any measure specifically 
intended to assess malingered pain. Qualitative 
comments suggested that respondents relied upon 
general pain and coping measures in their 
assessment of symptom validity, however, none of 
the measures cited incorporated validity scales 
practice 
Failed to report 
average number of 
assessments 
conducted in the 
last year 
80% coder 
agreement limits 
reliability 
Sullivan, 
Lange, 
& Dawes 
(2006) 
N = 17 
Members of the Australian 
Psychological Society, 
College of Clinical 
Neuropsychology and 
delegates from two 
Australian neuropsychology 
conferences were emailed an 
online survey 
Mean years of practice = 13 
years 
64% worked in private 
practice settings 
60% of respondents’ work 
was clinical assessment and 
the remainder forensic work 
Base rates of probable 
symptom exaggeration 
reported to be 17% of 
forensic cases, 13% of 
disability/personal injury 
assessments, and 4% of 
clinical cases 
(medical/psychiatric) 
The highest base rates 
were found in mild head 
injury cases and the lowest 
were associated with cases 
involving vascular 
dementia 
 
84% indicated they routinely screen for response 
validity in litigation cases, and 38% routinely 
screen in clinical cases 
Respondents reported considering an average of 
6.6/9 possible indicators when assessing response 
validity 
Methods most frequently endorsed by respondents 
were inconsistencies between severity of cognitive 
impairment and condition (68%), inconsistent 
pattern of performance and condition (66%), 
discrepancies between observations, self-reports 
and records (64%) and scores below cut-offs on 
SPVTs (59%) 
The most popular stand-alone PVTs were the Rey 
15-Item and the TOMM. The RAVLT recognition 
score was the most frequently endorsed embedded 
measure 
Not reported Very small sample 
size 
Not possible to 
report response rate 
due to design 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
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Slick, Tan, 
Strauss, & 
Hultsch 
(2004)  
N = 24 
North American 
neuropsychologists who 
were identified as experts in 
the area of civil litigation 
through their publication 
history  
Survey completed via email 
or over the telephone across 
a 3 month period 
61% response rate 
55% board certified in 
neuropsychology 
Mean years of practice = 15 
Majority (71%) had 
undertaken >20 assessments 
in the previous year 
Conducted both clinical and 
medico-legal evaluations 
50% of respondents 
considered base rates of 
possible malingering to be 
at least 10%, and a third 
considered rates to be at 
least 20% of cases 
Two-thirds considered 
there to be the presence of 
definite malingering in at 
least 10% of cases 
The majority (79%) used at least one PVT per 
assessment, and all respondents who employed a 
fixed battery approach reported they included a 
PVT routinely 
Multiple methods of assessing response validity 
were utilised; an average of 7.5/9 possible methods 
were considered by respondents when evaluating 
performance validity 
Most frequently used stand-alone PVTs were the 
TOMM and Rey15-Item 
89% of respondents reported they encouraged 
clients to try their best 
Respondents were divided on whether they gave 
examinees warning that tests are sensitive to invalid 
responding 
When suspecting invalid responding, the majority 
reported they would administer additional SPVTs 
(73%), and a minority would discontinue the 
assessment (16%)  
Over 90% indicated they often/always reported that 
test results were invalid, or inconsistent with injury 
severity. The majority (54%) reported never/rarely 
using the term malingering  
The average rating of 
confidence in respondents’ own 
abilities to detect response 
invalidity was 7.75/10 
Ratings were weakly correlated 
with reported base rates of 
definite malingering, but were 
strongly correlated with 
estimates of possible 
malingering (r=-.13, p=.44 and 
r=-.79, p<.01 respectively); a 
lower confidence in ability to 
detect malingering was reported 
by those who estimated higher 
prevalence of malingering 
Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Unclear whether 
base rates were 
estimates or 
accurate ratings  
Small sample size 
but good response 
rate 
Mittenberg, 
Patton, 
Canyock, & 
Condit (2002) 
N = 144 
Paper surveys were mailed 
to members of the American 
board of neuropsychologists 
who were listed as actively 
practising as 
neuropsychologists in the 
Base rates of probable 
malingering and symptom 
exaggeration were 
estimated to be 30% in 
disability evaluations, 29% 
in personal injury cases, 
19% in criminal cases and 
8% of medical cases; base 
The most common method for assessing response 
validity was comparing severity of injury/condition 
with severity of cognitive impairment (65%), or 
pattern of cognitive impairment (64%) 
57% relied upon scores below cut-offs on forced 
choice PVTs, and 38% utilised scores below cut-
Not reported Unstandardized 
survey limited by 
self-selection bias 
and self-report 
Proportion of 
clinical, medico-
legal and forensic 
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USA/Canada 
37% response rate 
Respondents engaged in 
both clinical and medico-
legal/forensic work 
Mean years of practice = 18 
Mean number of 
assessments undertaken 
yearly = 252 
rates did not vary greatly 
across practice settings or 
geographic regions, or the 
number of assessments 
conducted annually 
 
offs on SVTs  
Respondents endorsed an average of 7.5/9 possible 
validity indicators in forming a clinical opinion 
Presentations most likely to be associated with 
invalid performance in litigation settings were mild 
head injury (39%), fibromyalgia (35%), chronic 
pain (31%) and neurotoxic injuries (27%) 
 
 
assessments not 
reported 
 
Note. PVT = Performance validity Test; SVT = Symptom validity Test; SPVT = Symptom and performance validity test; NAN = National Academy of Neuropsychology; 
AACN = American Academy of Clinical Neuropsychology; INS = International Neuropsychological Society; TOMM = Test of Memory Malingering; MSVT = Medical 
Symptom Validity Test; WMT = Word Memory Test; RDS = Reliable Digit Span; CVLT-II = California Verbal Learning Test – Version 2; BRIEF = Behavior Rating 
Inventory of Executive Function; BASC-2 = Behavior Assessment System for Children - Version 2; mTBI = Mild traumatic brain injury; VA = Veterans Affairs; MMPI-II 
=  Minnesota Multiphasic Personality Inventory – Version 2; ACC = Accident Compensation Corporation; PAI = Personality Assessment Inventory
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Center for Evidence Based Management Quality Appraisal Tool (Section A) 
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Appendix D 
Broader Research and Clinical Implications of the Review (Section A) 
 
Broader Literature Research and Clinical Implications 
 
Service users’ 
experiences of testing 
 
One of the few studies exploring service-users’ experiences of 
neuropsychological assessments found half of the sample 
experienced significant fatigue and feelings of frustration, and a 
quarter indicated feeling anxious (Bennett-Levy, Klein-
Boonschate, Batchelor, McCarter, & Walton, 1994). Further 
research on this topic is needed to contextualise test performance, 
and to broaden clinicians’ beliefs about the meaning of SPVT 
failure. 
 
Clinicians’ 
experiences of talking 
with service users 
about response 
validity, for example, 
with regard to 
informed consent 
 
The review findings are linked to wider professional issues 
around informed consent, and how to negotiate this clinical 
dilemma when using SPVTs. Although professional 
recommendations provide limited guidance on providing warning 
to service-users that SPVTs will be used, this is by no means 
definitive and the issue of informed consent is not elaborated on 
by either the US or UK recommendations (McMillan et al., 2009; 
Bush et al., 2005; Heilbronner et al., 2009). 
 
The content of the 
professional 
recommendations 
themselves 
 
Francke, Smit, de Veer and Mistiaen (2008) carried out a 
systematic meta-review of factors affecting healthcare guidance 
adherence and found higher rates of implementation when 
guidelines were simply explained and easy to understand. The 
authors also found that targeted implementation interventions 
were necessary following the release of new guidance. Ferlie and 
Shortell (2001) argue that practice change interventions need to 
operate across multiple levels; individual clinicians, teams, 
organisations, and wider systems such as professional bodies. It 
may be that SPVT guidance needs to be more clearly 
communicated and disseminated in more accessible ways.  
 
Understanding 
differences in base 
rate in different 
settings  
 
The studies reviewed were suggestive of variable base rates of 
SPVT failure across different clinical settings and populations. 
This has important clinical implications for services in developing 
an understanding of what SPVT failure means in practice. This 
may involve consideration of the psychometric properties of 
SPVTs, confounding variables such as mood or cultural factors, or 
the potential for malingering. 
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Appendix E 
Approval Letter from Research Ethics Committee (Section B) 
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Appendix F 
Personality Assessment Inventory (PAI) Scale and Subscale Descriptions 
 
The PAI contains four validity scales. The Positive Impression Management (PIM), and 
Negative Impression Management (NIM) scales are concerned with the extent to which 
respondents present themselves in a favourable or unfavourable manner, and includes 
exaggerated, bizarre and highly unlikely symptoms. The Inconsistency (INC) scale identifies 
individuals who are not responding consistently to similar items. Finally, the Infrequency 
(INF) scale reflects the level of random or careless responding.  
The clinical scales of the PAI were developed based upon a construct validation framework in 
relation to psychiatric diagnostic categories relied upon at the time (Morey, 1991), and 
include Somatic Concerns (SOM), Anxiety (ANX), Anxiety Related Disorders (ARD), 
Depression (DEP), Mania (MAN), Paranoia (PAR), Schizophrenia (SCZ), Borderline features 
(BOR), Antisocial features (ANT), Alcohol Problems (ALC), and Drug Problems (DRG). 
The treatment consideration scales relate to factors that may influence engagement in 
treatment, and comprise Aggression (AGG), Suicidal Ideation (SUI), Nonsupport (NON), 
Stress (STR), and Treatment Rejection (RXR). Finally, the interpersonal scales explore 
Dominance (DOM) and Warmth (WAR).  
Morey (1991, 2007) suggests that t scores of 70 or above on a scale are suggestive of 
significant symptoms. 
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Appendix G 
End of Study Form to the Research Ethics Committee 
DECLARATION OF THE END OF A STUDY 
(For all studies except clinical trials of investigational medicinal products) 
To be completed in typescript by the Chief Investigator and submitted to the Research Ethics 
Committee (REC) that gave a favourable opinion of the research within 90 days of the conclusion 
of the study or within 15 days of early termination.   
For questions with Yes/No options please indicate answer in bold type. 
 
1. Details of Chief Investigator 
Name: 
Jessica Hooker 
Address: 
Salomons Centre for Applied Psychology, Canterbury Christ 
Church University, 1 Meadow Rd, Tunbridge Wells TN1 2YG 
Telephone: 
0333 011 7101 
Email: 
 
Fax: 
NA 
 
2. Details of study 
Full title of study: 
Effort test failure and psychological functioning in a UK NHS 
acquired brain injury population 
Research sponsor: 
Salomons Centre for Applied Psychology, Canterbury Christ 
Church University 
Name of REC: 
[removed to protect anonymity] 
REC reference number: 
16/LO/2092 
 
3. Study duration 
Date study commenced: 
25 February 2017 
Date study ended: 
09 March 2018 
Did this study terminate 
prematurely? 
Yes / No 
If yes, please complete sections 4, 5, 6, & 7.  
If no, please go direct to section 8. 
 
4. Recruitment 
Number of participants 
recruited 
 
Proposed number of 
participants to be recruited at 
the start of the study 
 
If different, please state the 
reason or this 
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5. Circumstances of early termination 
What is the justification for this 
early termination?  
 
 
6. Temporary halt 
Is this a temporary halt to the 
study? 
Yes / No 
If yes, what is the justification 
for temporarily halting the 
study?  
When do you expect the study 
to re-start? 
e.g. Safety, difficulties recruiting participants, trial has not 
commenced, other reasons. 
 
7. Potential implications for research participants 
Are there any potential 
implications for research 
participants as a result of 
terminating/halting the study 
prematurely?  
Please describe the steps 
taken to address them. 
 
 
8. Final report on the research 
Is a summary of the final 
report on the research 
enclosed with this form? 
Yes / No 
If no, please forward within 12 months of the end of the study. 
 
9. Declaration 
Signature of  
Chief Investigator: 
 
Print name: 
Jessica Hooker 
Date of submission: 
11 April 2018 
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Appendix H 
End of Study Report to the Research Ethics Committee and R&D Department 
 
Study title: Effort test failure and psychological functioning in a UK NHS acquired 
brain injury population 
REC reference: 16/LO/2092  
IRAS project ID: 216551 
 
Aims of the Study 
Neuropsychological assessments are not valid if the examinee does not try hard (exerts 
maximum effort) on the tests. Little research exists looking at the issue of effort in NHS 
populations. Performance validity tests (PVTs) and symptom validity tests (SVTs) have been 
recommended by the British Psychological Society to assist clinicians in validating 
assessment data. This study aimed to explore the prevalence (base rate) of PVT failure in the 
outpatient neuropsychology service, ___________________. A secondary aim was to 
investigate the relationship between PVT and SVT performance. Lastly, group differences in 
those passing and failing PVTs were explored in terms of demographics, and psychological 
functioning as measured by the Personality Assessment Inventory (PAI). Participants 
completed one stand-alone PVT (the Test of Memory Malingering [TOMM]), one embedded 
PVT (Digit Span age-corrected scaled score [DS-SS]), and one SVT (PAI validity scales]). 
 
Findings 
Anonymised archival neuropsychological test data (N = 127) spanning 2009 to 2014 were 
quantitatively analysed. The base rate of failure on any one PVT was 18%. The rate of 
TOMM failure was 12% and 4% additionally failed an embedded PVT. A significant 
relationship was found between PVT and SVT performance; participants who failed PVTs 
reported higher Negative Impression Management scores on the PAI than those who passed 
(p < .000, r = .34; medium effect size). Significant elevations were also found on the 
Schizophrenia (p < .000, r = -.32; medium effect size), Anxiety-Related Disorders (p = .002, 
r = -.27; small to medium effect size), and Paranoia (p = .003, r = -.26; small to medium 
effect size) PAI scales in those who failed one or more PVT compared to those who passed. 
Additionally, the PVT fail group attained significantly lower Full Scale IQ scores compared 
to the pass group (p < .000, r = -.37; medium effect size), but pre-morbid IQ scores were 
comparable across the groups. No other group differences on demographics were found. 
 
Conclusions and Implications 
Findings suggest that PVT failure occurs in a sizable minority of NHS acquired brain injury 
outpatients, which is unlikely to be simply explained by malingering for financial gain. 
Elevations in reported psychopathological symptoms may be related to emotional and 
cognitive sequalae resulting from the ABI itself. For example, the Schizophrenia scale could 
be considered to tap into cognitive or social difficulties arising from brain trauma, for 
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example ‘My thinking has become confused’, and ‘I just don’t seem to relate to people very 
well’. Careful interpretation of neuropsychological test data is recommended. It is hoped the 
current findings will inform UK psychologists in their clinical practice, and contribute to the 
provision of comprehensive and valid assessments of those who use these services. Research 
on this topic, as well as clinical practice, would benefit from continuing to explore the non-
neurological factors influencing performance, rather than focussing on malingering in 
isolation, in order to reduce false positive diagnoses and associated invalid recommendations. 
This study formed the major part of a doctoral thesis for a qualification in Clinical 
Psychology (DClinPsy) and will be examined by the Salomons Centre for Applied 
Psychology, Canterbury Christ Church University in April/May 2018. Presentation of 
findings to staff within the _____________ neuropsychology department has been 
provisionally arranged for 04 September 2018. Upon finalisation the project will be 
submitted to a peer reviewed journal. 
 
Please do not hesitate to contact me should you require any further information or have any 
questions. 
  
Jessica Hooker 
Trainee clinical psychologist 
Salomon’s Centre for Applied Psychology 
Canterbury Christ Church University 
1 Meadow Road 
Tunbridge Wells 
TN1 2YG 
Tel:  01227 92 7073 
Email:  
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Appendix I 
Description of Joint Work 
 
Section B was conducted in part collaboration with a University College London 
DClinPsy student, Anna Isherwood, whose thesis was completed in early 2018. The current 
study focused on performance validity testing in terms of differences in symptom validity test 
performance and self-reported affective and personality variables. My colleague’s thesis 
aimed to explore the presence of a general downgrading of abilities across multiple domains 
of cognitive functioning in PVT fail groups. Only a subset of the data was shared between the 
projects (57%) and my colleague additionally accessed separate data from a different research 
site. Completion of the archival database was done jointly. Ethical applications, analysis and 
write-up has been conducted separately. 
 
  
APPENDICES OF SUPPORTING MATERIAL 
129 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
Appendix J 
Instructions for Submission to The Clinical Neuropsychologist 
 
Instructions for authors 
Thank you for choosing to submit your paper to us. These instructions will ensure we have 
everything required so your paper can move through peer review, production and publication 
smoothly. Please take the time to read and follow them as closely as possible, as doing so will 
ensure your paper matches the journal's requirements. For general guidance on the publication 
process at Taylor & Francis please visit our Author Services website.  
 
 
  
This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer review 
manuscript submissions. Please read the guide for ScholarOne authors before making a 
submission. Complete guidelines for preparing and submitting your manuscript to this journal are 
provided below.  
Contents 
• About the Journal 
• Peer Review 
• Preparing Your Paper 
o Structure 
o Word Limits 
o Style Guidelines 
o Formatting and Templates 
o References 
o Checklist 
• Using Third-Party Material 
• Submitting Your Paper 
• Data Sharing Policy 
• Publication Charges 
• Copyright Options 
• Complying with Funding Agencies 
• Open Access 
• My Authored Works 
• Reprints 
About the Journal 
The Clinical Neuropsychologist is an international, peer-reviewed journal publishing 
high-quality, original research. Please see the journal's Aims & Scope for information 
about its focus and peer-review policy. 
Please note that this journal only publishes manuscripts in English. 
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The Clinical Neuropsychologist accepts the following types of article: Original 
Articles, Review Articles, Grand Rounds Articles, Book Reviews. 
Authors are strongly encouraged to consult the TCN reporting guidelines checklist 
when preparing or editing their manuscript. Gross disregard for the reporting 
guidelines could result in the manuscript being returned without a review. 
Peer Review 
Taylor & Francis is committed to peer-review integrity and upholding the highest 
standards of review. Once your paper has been assessed for suitability by the editor, 
it will then be single blind peer reviewed by independent, anonymous expert 
referees. Find out more about what to expect during peer review and read our 
guidance on publishing ethics. 
Preparing Your Paper 
Structure 
Your paper should be compiled in the following order: title page; abstract; keywords; 
main text introduction, materials and methods, results, discussion; 
acknowledgments; declaration of interest statement; references; appendices (as 
appropriate); table(s) with caption(s) (on individual pages); figures; figure captions 
(as a list). 
Word Limits 
Please include a word count for your paper. There are no word limits for papers in 
this journal. 
Style Guidelines 
Please refer to these quick style guidelines when preparing your paper, rather than 
any published articles or a sample copy. 
Please use American spelling style consistently throughout your manuscript. 
Please use single quotation marks, except where ‘a quotation is “within” a quotation’. 
Please note that long quotations should be indented without quotation marks. 
Headers should be in sentence case. p - lower case and italicised. P-values should 
not have a zero before the decimal point. n - lower case and italicised SD - upper 
case and italicised ns - lower case and italicised. 
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Formatting and Templates 
Papers may be submitted in Word or LaTeX formats. Figures should be saved 
separately from the text. To assist you in preparing your paper, we provide 
formatting template(s). 
Word templates are available for this journal. Please save the template to your hard 
drive, ready for use. 
A LaTeX template is available for this journal. Please save the LaTeX template to 
your hard drive and open it, ready for use, by clicking on the icon in Windows 
Explorer. 
If you are not able to use the template via the links (or if you have any other template 
queries) please contact authortemplate@tandf.co.uk. 
References 
Please use this reference guide when preparing your paper. 
An EndNote output style is also available to assist you. 
Checklist: What to Include 
1. Author details. Please include all authors’ full names, affiliations, postal addresses, 
telephone numbers and email addresses on the cover page. Where available, please also 
include ORCiDs and social media handles (Facebook, Twitter or LinkedIn). One author will 
need to be identified as the corresponding author, with their email address normally 
displayed in the article PDF (depending on the journal) and the online article. Authors’ 
affiliations are the affiliations where the research was conducted. If any of the named co-
authors moves affiliation during the peer-review process, the new affiliation can be given as 
a footnote. Please note that no changes to affiliation can be made after your paper is 
accepted. Read more on authorship. 
2. Should contain a structured abstract of 250 words. A structured abstract should cover (in the 
following order): Objective: A brief statement of the purpose of the study. Method: A 
summary of the participants as well as descriptions of the study design, procedures, and 
specific key measures, to the extent that space allows. Results: A summary of the key 
findings. Conclusions: Clinical and theoretical implications of the findings. NOTE: If your 
manuscript is a critical review or a commentary, you can omit the Results portion of the 
abstract. However, retain that portion for systematic reviews and meta-analyses. Read tips 
on writing your abstract. 
3. Graphical abstract (optional). This is an image to give readers a clear idea of the content of 
your article. It should be a maximum width of 525 pixels. If your image is narrower than 525 
pixels, please place it on a white background 525 pixels wide to ensure the dimensions are 
maintained. Save the graphical abstract as a .jpg, .png, or .gif. Please do not embed it in the 
manuscript file but save it as a separate file, labelled GraphicalAbstract1. 
4. You can opt to include a video abstract with your article. Find out how these can help your 
work reach a wider audience, and what to think about when filming. 
5. Read making your article more discoverable, including information on choosing a title and 
search engine optimization. 
6. Funding details. Please supply all details required by your funding and grant-awarding 
bodies as follows:  
For single agency grants  
APPENDICES OF SUPPORTING MATERIAL 
132 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
This work was supported by the [Funding Agency] under Grant [number xxxx].  
For multiple agency grants  
This work was supported by the [Funding Agency #1] under Grant [number xxxx]; [Funding 
Agency #2] under Grant [number xxxx]; and [Funding Agency #3] under Grant [number 
xxxx]. 
7. Disclosure statement. This is to acknowledge any financial interest or benefit that has 
arisen from the direct applications of your research. Further guidance on what is a conflict of 
interest and how to disclose it. 
8. Data availability statement. If there is a data set associated with the paper, please provide 
information about where the data supporting the results or analyses presented in the paper 
can be found. Where applicable, this should include the hyperlink, DOI or other persistent 
identifier associated with the data set(s). Templates are also available to support authors. 
9. Data deposition. If you choose to share or make the data underlying the study open, please 
deposit your data in a recognized data repository prior to or at the time of submission. You 
will be asked to provide the DOI, pre-reserved DOI, or other persistent identifier for the data 
set. 
10. Geolocation information. Submitting a geolocation information section, as a separate 
paragraph before your acknowledgements, means we can index your paper’s study area 
accurately in JournalMap’s geographic literature database and make your article more 
discoverable to others. More information. 
11. Supplemental online material. Supplemental material can be a video, dataset, fileset, 
sound file or anything which supports (and is pertinent to) your paper. We publish 
supplemental material online via Figshare. Find out more about supplemental material and 
how to submit it with your article. 
12. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 300 
dpi for colour, at the correct size). Figures should be supplied in one of our preferred file 
formats: EPS, PS, JPEG, GIF, or Microsoft Word (DOC or DOCX). For information relating to 
other file types, please consult our Submission of electronic artwork document. 
13. Tables. Tables should present new information rather than duplicating what is in the text. 
Readers should be able to interpret the table without reference to the text. Please supply 
editable files. 
14. Equations. If you are submitting your manuscript as a Word document, please ensure that 
equations are editable. More information about mathematical symbols and equations. 
15. Units. Please use SI units (non-italicized). 
Using Third-Party Material in your Paper 
You must obtain the necessary permission to reuse third-party material in your 
article. The use of short extracts of text and some other types of material is usually 
permitted, on a limited basis, for the purposes of criticism and review without 
securing formal permission. If you wish to include any material in your paper for 
which you do not hold copyright, and which is not covered by this informal 
agreement, you will need to obtain written permission from the copyright owner prior 
to submission. More information on requesting permission to reproduce work(s) 
under copyright. 
Submitting Your Paper 
This journal uses ScholarOne Manuscripts to manage the peer-review process. If 
you haven't submitted a paper to this journal before, you will need to create an 
account in ScholarOne. Please read the guidelines above and then submit your 
paper in the relevant Author Centre, where you will find user guides and a helpdesk. 
APPENDICES OF SUPPORTING MATERIAL 
133 
CLINICIAN VALIDITY TESTING BELIEFS AND PRACTICES 
 
 
If you are submitting in LaTeX, please convert the files to PDF beforehand (you will 
also need to upload your LaTeX source files with the PDF). 
Please note that The Clinical Neuropsychologist uses Crossref™ to screen papers 
for unoriginal material. By submitting your paper to The Clinical 
Neuropsychologist you are agreeing to originality checks during the peer-review and 
production processes. 
On acceptance, we recommend that you keep a copy of your Accepted Manuscript. 
Find out more about sharing your work. 
Data Sharing Policy 
This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are 
encouraged to share or make open the data supporting the results or analyses 
presented in their paper where this does not violate the protection of human subjects 
or other valid privacy or security concerns. 
Authors are encouraged to deposit the dataset(s) in a recognized data repository 
that can mint a persistent digital identifier, preferably a digital object identifier (DOI) 
and recognizes a long-term preservation plan. If you are uncertain about where to 
deposit your data, please see this information regarding repositories. 
Authors are further encouraged to cite any data sets referenced in the article and 
provide a Data Availability Statement. 
At the point of submission, you will be asked if there is a data set associated with the 
paper. If you reply yes, you will be asked to provide the DOI, pre-registered DOI, 
hyperlink, or other persistent identifier associated with the data set(s). If you have 
selected to provide a pre-registered DOI, please be prepared to share the reviewer 
URL associated with your data deposit, upon request by reviewers. 
Where one or multiple data sets are associated with a manuscript, these are not 
formally peer reviewed as a part of the journal submission process. It is the author’s 
responsibility to ensure the soundness of data. Any errors in the data rest solely with 
the producers of the data set(s). 
Publication Charges 
There are no submission fees or page charges for this journal. 
Colour figures will be reproduced in colour in your online article free of charge. If it is 
necessary for the figures to be reproduced in colour in the print version, a charge will 
apply. 
Charges for colour figures in print are £300 per figure ($400 US Dollars; $500 
Australian Dollars; €350). For more than 4 colour figures, figures 5 and above will be 
charged at £50 per figure ($75 US Dollars; $100 Australian Dollars; €65). Depending 
on your location, these charges may be subject to local taxes. 
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Copyright Options 
Copyright allows you to protect your original material, and stop others from using 
your work without your permission. Taylor & Francis offers a number of different 
license and reuse options, including Creative Commons licenses when publishing 
open access. Read more on publishing agreements. 
Complying with Funding Agencies 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers into 
PubMedCentral on behalf of authors, meeting the requirements of their respective 
open access policies. If this applies to you, please tell our production team when you 
receive your article proofs, so we can do this for you. Check funders’ open access 
policy mandates here. Find out more about sharing your work. 
Open Access 
This journal gives authors the option to publish open access via our Open Select 
publishing program, making it free to access online immediately on publication. Many 
funders mandate publishing your research open access; you can check open access 
funder policies and mandates here. 
Taylor & Francis Open Select gives you, your institution or funder the option of 
paying an article publishing charge (APC) to make an article open access. Please 
contact openaccess@tandf.co.uk if you would like to find out more, or go to 
our Author Services website. 
For more information on license options, embargo periods and APCs for this journal 
please go here. 
My Authored Works 
On publication, you will be able to view, download and check your article’s metrics 
(downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis 
Online. This is where you can access every article you have published with us, as 
well as your free eprints link, so you can quickly and easily share your work with 
friends and colleagues. 
We are committed to promoting and increasing the visibility of your article. Here are 
some tips and ideas on how you can work with us to promote your research. 
Article Reprints 
You will be sent a link to order article reprints via your account in our production 
system. For enquiries about reprints, please contact the Taylor & Francis Author 
Services team at reprints@tandf.co.uk. You can also order print copies of the journal 
issue in which your article appears. 
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Queries 
Should you have any queries, please visit our Author Services website or contact us 
at authorqueries@tandf.co.uk. 
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